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ABSTRACT 
!
The cellular form of the prion protein (PrPC) is a sialoglycoprotein ubiquitously expressed 
in the central nervous system (CNS) of mammalian species along the neurodevelopment 
and in the adulthood. The PrPC localization in the brain has attracted interest because of its 
involvement in fatal neurodegenerative disorders, denoted as transmissible spongiform 
encephalopathies. In mammals, PrPC is expressed early in embryogenesis, and in the 
adulthood it reaches its highest levels in the neurons of the encephalon and spinal cord. The 
protein is also found at lower levels in glial cells of the CNS, as well as in almost all 
peripheral cell types. By combining in situ hybridization and immunohistochemical 
techniques, we show the earliest expression of the protein in mouse hippocampus, thalamus 
and hypothalamus. In particular, specific white matter fiber tracts in mouse CNS (the 
hippocampal fimbria, the stria terminalis, and the fasciculus retroflexus) show the highest 
expression of the protein. To extend our understanding of varying PrPC expression profiles 
in different mammals, we carried out a detailed expression analysis of PrPC distribution 
along the neurodevelopment of the metatherian South American short-tailed opossum 
(Monodelphis domestica). No naturally occurring prion diseases have been reported yet for 
this species. Compared with mice, in opossums we detected lower levels of PrPC in the 
white matter fiber bundles of the CNS. This result might offer new insights into a possible 
involvement of PrPC in the varying susceptibility to prion diseases for different mammals. 
The different distribution of PrPC in the hippocampal layers of mammals led us to 
hypothesize a different physiological relevance of PrPC in this region. To better understand 
this issue, we used PrP knock-out mice, in which PrPC is not expressed in the hippocampal 
strata. We observed that the absence of PrPC impairs the signaling pathway promoted by 
Reelin, a protein of the extracellular matrix expressed in the stratum lacunosum molecolare 
and hippocampus of the early postnatal mouse. Overall, our findings suggest a possible role 
for PrPC in the modulation of the events triggered by the Reelin-signaling pathway in the 
developmental mouse hippocampus. 
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Chapter One 
!
INTRODUCTION 
!
The cellular form of the prion protein (PrP), PrPC, is a sialoglycoprotein ubiquitously 
expressed in the central nervous system (CNS) of a wide range of species, form fish to 
mammals. Several studies based on physiological abnormalities in PrP-knockout mice or in 
cells derived from them, have suggested the involvement of PrPC in a plethora of 
physiological functions including synaptic plasticity, protection against oxidative stress, 
cell-adhesion, neuronal excitability and neurite outgrowth and maintenance of white 
matter. However, the underlying molecular mechanisms have not been fully clarified yet. 
Mapping the regional distribution of PrPC in different mammals and analyzing its 
involvement in physiological pathways may help to decipher the physiological role of PrPC 
in the CNS. This study might also contribute to explain the toxic phenotypes observed in 
prion disorders or transmissible spongiform encephalopathies (TSEs), caused by the 
conversion of PrPC into a pathogenic isoform called PrPSc. 
 
1.1 Biogenesis of PrPC, the cellular prion protein 
The mature form of PrPC is composed of 209 amino acids (aa) (hereafter in human 
numbering). NMR spectroscopy studies show a predominantly "-helical folded protein 
with a C-terminal structured domain from residues 128 to 231 [1] and a #exible disordered 
N-terminal region including a series of octapeptide repeat units [2,3] enriched in histidine 
(His) residues, which can bind bivalent metal ions such as copper, zinc and manganese [4]. 
In the endoplasmatic reticulum (ER) the immature form of PrP undergoes some post-
translational modifications. The N-terminal signal peptide (residues 1-22) is removed and a 
! *)!
single disulphide bridge is formed between two cysteines (Cys) in the C-terminal. The 
subsequent cleavage of a carboxy-terminal signal sequence precedes the attachment of the 
glycosylphosphatidylinositol (GPI) moiety at residue 230. In mouse PrPC, two N-linked 
oligosaccharide chains may also be added to asparagines 180 and 196 (corresponding to 
Asn181 and Asn197 in human numbering). The protein is then trafficked to the Golgi 
apparatus where the N-linked oligosaccharides are further processed, thus resulting in 
modified glycosylation to include complex sugar molecules. Following these 
modifications, PrP is further trafficked to the cell surface, where it preferentially localizes 
in the lipid raft fractions via the GPI-anchor [5]. The protein is partially endocytosed via 
clathrin coated-pits. The subcellular localization and processing of PrPC may also present 
different topological isoforms of the protein, namely CtmPrP and the NtmPrP. The former is 
believed to span the membrane once, with its highly conserved hydrophobic region in the 
center of the molecule (residues 111-134) as a transmembrane anchor and the C terminus in 
the ER lumen. The latter spans the membrane with the same transmembrane segment, but 
with its N-terminal reversed in the ER lumen [6]. Besides the existence of topological 
isomers of PrP, it has also been observed that part of the protein is proteolitically cleaved 
by cellular proteases near amino acid residues 110–111, resulting in N-terminal and C-
terminal fragments called N1 and C1, respectively [7]. 
Both N-linked glycosylation sites in all mammalian PrP genes analyzed to date appeared to 
be conserved. This hints at a functional significance for this post-translational modification. 
Indeed, depending on the number of glycosylation sites occupied with oligosaccharide 
chains, PrP can be unglycosylated, monoglycosylated or diglycosylated.  
The internalization of PrPC is still debated, because either raft/caveolae or caveolae-like 
endocytosis [8], [9,10] as well as clathrin-dependent endocytosis may be occurring [11], 
[12]. The constitutive endocytosis of PrPC by clathrin-coated vesicles seems to be 
influenced by the interaction of the positively charged N-terminal motif KKRPKP with a 
transmembrane protein [13]. Major questions remain unanswered as to the physiological 
regulation of the endocytic cycle of PrPC. This subject requires further investigations, 
especially because of its possible involvement in physiological PrPC-mediated signaling 
mechanisms. 
! "+!
 
2. PrPC structure 
High-resolution NMR studies of bacterially expressed recombinant (rec) PrP — a model 
for PrPC lacking any post-translational modi$cations — have revealed a folded C-terminal 
domain and an N-terminal unstructured region. The PrP globular domain is highly 
conserved among mammals. It consists of two short %-strands and three "-helices, with a 
disul$de bond bridging "-helices 2 and 3 [1]. The structure of the globular half of the 
human PrPC is identical to that of several other mammals. Notably, despite the low 
sequence identity between mammalian and non mammalian PrPC, the structural features of 
PrPC are remarkably preserved [14]. 
 
2.1. The N-terminal unstructured domain 
The flexible and disordered N-terminal half of PrPC (or NH2-PrPC) may be divided into 
four different domains: a first charged cluster (CC1); the octapeptide repeat (OR); a second 
charge cluster or CC2; and a hydrophobic domain-termed (HD) (Fig. 1.1). Remarkably, 
several segments of this flexible region are highly conserved in different mammalian 
species, suggesting their strong functional significance [15,16]. 
! "*!
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Figure 1.1. The NH2-PrPC domains: CC1, OR, CC2 and HD represent the charged cluster 
1 (aa 23–28), the octapeptide repeat (aa 51–91), the charged cluster 2 (aa 100–109), and the 
hydrophobic domain (aa 112–133), respectively. 
!
The presence of an unstructured N-terminal domain qualifies PrPC as a partially 
intrinsically unstructured or disordered protein [17]. Intrinsically disordered proteins are 
characterized by: 
1. their function in molecular recognition; 
2. their ability to interact with multiple partners including themselves using the same 
#exible region; 
3. their unfolded-to-folded transition upon binding to functional partners [18].  
Similarly to other unstructured proteins, PrPC can bind different ligands. The N-terminal of 
the recPrP has been shown to bind small unilamellar vesicles containing anionic lipids at 
pH 7.4 via both electrostatic and hydrophobic interactions [19]. It is also important for 
nucleic acid binding activity [20]. Furthermore, NH2-PrPC has been shown to play a role for 
several extracellular and transmembrane proteins, namely: stress-inducible protein 1 [21], 
low-density lipoprotein receptor-related protein 1 [22], neuronal cell adhesion molecules 
(NCAM) and A% oligomers [23]. The binding diversity agrees with PrPC being involved in 
different biological processes [24,25]. Many ligands binding to NH2-PrPC trigger a rapid 
internalization of PrPC, and endocytosis is likely to be an important feature for the 
physiological function of PrPC. The combination of binding diversity and ligand-induced 
! ""!
endocytosis supports a role for PrPC as a broad-spectrum molecular sensor at the cell 
surface. 
 
2.2. The C-terminal globular domain 
The C-terminal domain of PrPC is characterized by 3 "-helices (H1, H2, H3) and a short, 
double-stranded, antiparallel ß-sheet (S1, S2) [1]. A disulfide bridge between Cys179 and 
Cys214 anchors H2 and H3 (Fig 1.2). 
 
 
!
Figure 1.2. Overall fold of PrPC. Ribbon representation of the C̻terminal structured 
domain of mouse PrP. The secondary structure elements and the N̻ and C̻termini are 
labeled. The disulphide bridge is depicted in yellow [Modified from [26]]. 
!
The NMR structures of PrPC from different species have been resolved in an attempt to 
understanding both the relation to disease-causing mutations and the molecular bases of the 
so-called specie barrier. Local sequence and structure variations are most prominently 
localized at the interface between the %2–"2 loop (residues 165-175) and in the C-terminal 
of !3 helix (residues 215-228) (Figure 1.2). This localization provides insights into these 
sub-domains of potential importance for pathogenicity and specie barriers to disease 
! "#!
transmission across species. Indeed, while this loop is highly flexible in most species, it 
shows a well-defined conformation in the PrP structures of Syrian hamster [27], elk [28], 
bank vole [29], wallaby [30], rabbit [31] and horse [32]. In elk and bank vole PrP, this 
rigidity was shown to be controlled by a single amino acid substitution, S170N, within the 
loop, whereas in wallaby, rabbit and horse PrP it correlates with a long-range interaction 
between residue 166 in the %2–"2 loop and residue 225 in the "3 helix. Different 
experimental studies suggested that the conformation of the %2–"2 loop plays a role in TSE 
transmission and susceptibility. It has been postulated that mammals carrying a flexible %2–
"2 loop could be easily infected by prions, whereas prions are not very efficiently 
transmitted to animals carrying a rigid loop [33]. Notably, horse and rabbit display 
resistance to prion infections and do not develop spontaneous prion diseases. However, 
under controlled laboratory conditions, prions are able to adapt and infect species 
previously believed to be TSE resistant, as was recently reported in rabbits infected by the 
murine ME7 prion strain using protein misfolding cyclic amplification (PMCA) techniques 
[34-37]. NMR studies showed that their PrP structures are characterized by a rigid %2–"2 
loop, and by closer contacts between the loop and !3 helix. Thus, prion resistance seems to 
be enciphered by the amino acidic composition of the %2–"2 loop, and its long-range 
interactions with residues in the C-terminal end of "3 helix [34-37]. 
! "$!
3. PrPC functions in the nervous system 
The physiological role of PrPC is usually disregarded at the expense of its role in TSEs. The 
high level of PrPC expression in the CNS and the conserved motifs in its structure suggest 
that protein may play an important role in cellular function. 
 
3.1. PrP knock-out mice 
Molecular cloning of the cDNA encoding the entire open reading frame (ORF) of mouse 
Prnp [38] and the use of homologous recombination has allowed for the generation of mice 
in which the Prnp gene is deleted. All PrP-null animals generated to date have confirmed a 
tight correlation between the expression of PrPC and the sensitivity to prion infection. 
Genetic ablation of PrPC expression in mice, either prenatally or postnatally, produces 
relatively little phenotypic effect other than an inability to propagate prions [39]. 
The first PrP-null mouse strain was generated in a mixed C57BL/6J & 129/Sv(ev) 
background, by replacing codons 4-187 with a neomycin phosphotransferase (neo) 
expression cassette [40]. These animals, designated Prnp0/0 or Zürich I (ZrchI), did not 
show gross abnormalities in the overall phenotype. 
A second line of PrP knock-out mice was produced by interrupting the Prnp ORF at 
position 93 (a Kpn 1 site) and introducing a neo cassette [41]. These mice are known as 
Edinburgh (Edbg) Prnp-/-, and are under 129/Ola genetic background. Like the ZrchI, they 
do not show any developmental alteration. 
In sharp contrast with the ZrchI and the Edbg mice, the Nagasaki Prnp-ablated mice (Ngsk) 
develop severe ataxia and Purkinje cell degeneration at advanced ages. In the Ngsk mice, 
besides the Prnp ORF, 0.9 kb of intron 2, 10 bp of the 5’-oncoding region, 0.45 kb of the 
3’-noncoding region have also been replaced by the neo cassette [42]. Since the observed 
phenotype is abolished by the reintroduction of Prnp, this phenotype was attributed to the 
absence of PrPC. The same phenotype has been shown in other knock-out mice such as 
Rcm0 mice and in Zurich II (ZrchII) mice. In the latter, the Prnp ORF, 0.26 kb of intron 2, 
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10 bp of the 5’-noncoding region, the 3’-noncoding region of exon 3 plus 0.6 kb of the 
adjacent region were removed [43]. 
It has been shown that the distinct phenotypes of Ngsk, Rcm0, ZrchII mice are due to the 
gene deletion approach. In fact it has been shown that ataxia in these animals is caused by 
overexpression of another protein denominated Doppel (Dpl), a protein encoded by the 
Prnd gene, located at 16 kb downstream of Prnp. The ectopic expression of Dpl in ZrchII 
mice causes ataxia and degeneration of cerebellar granule and Purkinje cells, and its levels 
are inversely correlated with the onset of the disease [44]. The ectopic expression of Dpl, 
rather than the deletion of the Prnp gene is responsible for neurodegeneration. Notably, the 
reintroduction of Prnp in mice overexpressing Dpl in the brain rescues the phenotype [45].  
PrPC thus counteracts Dpl neurotoxicity, but the mechanism underlying this antagonism is 
still controversial [46]. 
 
3.2. Neurodegeneration in other transgenic mice 
Two constructs have been used to generate mice overexpressing PrPC. The first one was a 
large cosmid composed of three exons and two introns of the mouse Prnpb allele (108 Phe, 
189 Val). Mice overexpressing PrPC encoded by this construct develop ataxia, hind limb 
paralysis, and tremors. The second genetic construct, called half-genomic DNA, was 
derived from the former by deleting intron 2 and replacing exon 3 by the Prnpa allele 
(108Leu, 189Thr) and the 18 kb of the 3’-sequence by a 2.2 kb downstream sequence from 
the Prnpa locus. Mice carrying the half-genomic DNA do not show an obvious phenotype 
[47]. The half genomic PrP vector was also used to clone deletion mutants of the Prnpa 
allele, which were then expressed as transgenes in ZrchI Prnp0/0 animals. (Fig 3.1 -
modified from [25]) 
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Figure 3.1. PrPC deletion mutants expressed in Prnp0/0 mice and their neurodegenerative 
phenotypes. The wild-type (WT) PrPC molecule with major domains annotated is shown at 
the top. Deleted domains are replaced by a solid black line and the deleted amino acids are 
indicated to the right of each diagram ('). The presence or absence of neurodegeneration 
(NDG) is indicated [25]. 
 
It has been shown that deletion of aa 32–121, or 32–134, leads to both severe ataxia and 
apoptosis in the cerebellum of relatively young animals. This phenotype is rescued by 
introducing one copy of a WT Prnp gene [48]. 
Mice expressing PrP'32-134 and mice overexpressing Dpl share a similar phenotype 
suggesting that the Dpl and PrP'32-134 may promote the same kind of neurodegeneration. 
However, overexpression of Dpl leads to massive degeneration of Purkinje cells, whereas 
PrP'32-134 causes degeneration in the granule cell layer [42]. 
Mice expressing Dpl or one of the truncated forms PrP'32-121 or PrP'32-134 are characterized 
by severe demyelination and axon loss in the spinal cord and in the cerebellar white matter. 
! "'!
The oligodendrocyte-specific expression of PrPC can rescue leukodystrophy but not 
cerebellar granule cell degeneration [49]. 
Interestingly, two-week-old mice expressing truncated PrP'105-125 are characterized by 
cerebellar atrophy, severe loss of cerebellar granule cells, gliosis and astrocytic 
hypertrophy. Mice expressing PrP'94-134 showed a lethal phenotype which was rescued 
dose-dependently either by WT PrPC or a PrPC lacking all octarepeats. Mice with the 
PrP'114-121 deletion did not show a particular phenotype and the expression of this smaller 
mutation ameliorated the phenotype caused by truncated PrP'32-134 but worsened the 
degenerative effect of PrP'94-134. Several mechanisms have been proposed to elucidate how 
the truncated forms of PrPC induce degeneration. Baumann et al. suggest that dimers of 
truncated PrP'32-134 would trap a putative PrPC receptor in a dominant-negative form and 
thus hamper signals for myelin maintenance. The presence of the octarepeat region in the 
PrP'94-134 can generate a more stable dominant-negative form of the receptor, leading to a 
more severe pathology than the truncated PrP'32-134 [50]. Alternatively, the higher affinity 
of the truncated PrP'105-125 compared with that of PrP'32-134 for a putative PrPC receptor 
causes a more severe neurodegeneration. The putative PrPC receptor may show an altered 
conformation in presence of the centrally truncated PrPC leading to neurotoxic signals [51]. 
Furthermore, in PrPC null background mice PrP'105-125 causes cerebellar degeneration [51] 
whereas PrP'114-121 does not. This suggests that these two truncated PrP may exert different 
activities. 
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3.3. Marsupials as a model organism in prion biology 
The sequence identity of PrPC among mammals suggests an essential physiological role. 
Defining the function of PrPC is also a prerequisite for understanding TSEs, or prion 
diseases, as they are attributed to the post-translational conversion of PrPC into a misfolded, 
pathogenic form denoted prion or PrPSc [52]. A still controversial aspect in TSEs is the 
different ability of prions to infect some mammalian species and not others. Although it has 
been recently demonstrated that under forced laboratory conditions rabbits are not resistant 
to prion infection, so far no naturally occurring TSEs have been reported in rabbit, horse or 
any marsupial species. A possible explanation for this argues that the PrPC primary 
sequence, together with local structural variations within the C-terminal globular domain, 
might account for prion resistance in different mammals. However, little is known about 
the regional distribution of PrPC in the CNS of mammalian species that seem resistant to 
TSEs. Differences in PrPC expression in mammalian species, for which no naturally 
occurring TSE has been reported, may shed new light on different susceptibility to these 
maladies [33].!
Several animals have been used to study neurodegeneration and pathology of the human 
CNS. For instance, marsupials have been used to investigate developmental white matter 
damage, a brain pathology associated with several long-term neurological disorders [53]. 
 
3.3.1. The Monodelphis domestica 
The metatherian mammal South American short-tailed opossum (Monodelphis domestica) 
(hereafter Op) has been used as animal model in biomedical research. The laboratory Op is 
used in a broad range of research programs focused on development, physiology and 
disease susceptibility. This animal model is used in developmental studies mainly because 
of the rudimental stage of development of the newborn pups, which resemble 11- or 12-
day-old mouse embryos [54,55]. In the newborn Op pup the CNS is still at an embryonic 
stage [54], because its development is completed during postnatal life, thus making 
experimental studies less invasive. Figure 4.1 shows the Op at different developmental 
stages. 
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Figure 4.1. The Monodelphis domestica at different development stages. (A-C) pups 9 
(P9), 20 (P20) and 40 days (P40) after birth. Bars: 1 cm. 
 
The Op is the first metatherian species whose genome has been sequenced, providing 
insights into the evolution and organization of mammalian genomes [56]. The strategic 
importance of the Op genome sequence accrues from both the unique phylogenetic position 
of marsupials, which distinguish them from other mammalian species. Owing to their close 
relationship, marsupials and placentals share fundamentally similar genetic structures and 
molecular processes. However, during their long evolutionary separation, these mammals 
have developed distinctive anatomical, physiologic, and genetic features that hold 
tremendous potential for examining relationships between the molecular structures of 
mammalian genomes and the functional attributes of their components [57]. Judging from 
the multiple nuclear sequence, the most closely related mammalian lineages are Methateria 
and Eutheria, which diverged from their common mammalian ancestor  
~173-190 million years ago (Fig. 4.2). 
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Figure 4.2. Phylogenetic splitting topology and approximate ages for mammalian 
divergences. Shaded boxes indicate approximate ranges for divergence date. Approximate 
dates for the earliest (deepest) divergences among extant species within the eutherian and 
metatherian lineages are indicated by arrowheads. As for the branching points, the shaded 
boxes associated with arrowheads indicate approximate range estimates for these basal 
divergence dates. (From [57]). 
 
Because of their close evolutionary position, marsupial and placental mammals share 
similar genetic structures and molecular processes, reflecting elemental and ancient 
mammalian characteristic. Each group has then developed its own unique morphologic and 
physiologic features on these elemental patterns. Due to its peculiar position in the 
phylogenetic tree, the methaterian Op has developed unique features that retain an 
extraordinary potential for understanding the CNS physiology. Furthermore, its small size, 
ease of care and the non-seasonal breeding make Op a suitable laboratory animal model 
[58]. 
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4. CNS Cellular Processes Influenced by PrPC 
The PrPC has been hypothesized to be involved in numerous physiological functions 
including neuronal cell survival, neurite outgrowth, synapses formation and function, and 
maintenance of myelinated fibers (Figure 4.3). 
 
!
Figure 4.3. Schematic representation of CNS processes influenced by PrPC. [59] 
 
In vitro and in vivo studies have shown that PrPC has a survival-promoting effect on 
neuronal and non-neuronal cells that is mainly mediated by antiapoptotic or antioxidative 
mechanisms [60]. 
 
4.1. Anti-apoptotic function 
Studies on human primary neurons have shown that PrPC potently inhibits Bax-induced cell 
death. The deletion of four octapeptide repeats of PrP (PrP'OR) and familial D178N and 
T183A PrP mutations completely or partially eliminate the neuroprotective effect of PrPC. 
PrP remains antiapoptotic despite truncation of the GPI anchor signal peptide. This 
indicates that the neuroprotective form of PrP does not require the abundant, cell surface 
GPI-anchored PrP [61]. 
In post-ischemic rodent brain, PrPC expression increases in a time-dependent manner [62]. 
In addition, overexpression of PrPC transduced by adenovirus-mediated gene transfer could 
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reduce ischemic injury and improve neurological dysfunction after cerebral ischemia in rats 
[62]. The post ischemic caspase-3 activation is enhanced in PrPC knock-out mice and the 
increased activation of ERK1/2, STAT-1 and JNK 1/-2 suggests a possible role for PrPC in 
signaling pathway [63]. Furthermore, the reduced levels of phospho-Akt in the gray matter 
suggest an impairment of the antiapoptotic phosphatidylinositol 3-kinase/Akt pathway in 
mice lacking PrPC. 
 
4.2 Protection against oxidative damage 
Several lines of evidence suggest an antioxidative effect for PrPC. Studies in primary 
cerebellar granule neuron cultures exposed to hydrogen peroxide have shown that PrPC 
knock-out neurons are significantly more susceptible than WT neurons after 6 and 24 hours 
of exposure [64]. In vivo studies have shown that in presence of PrPC the activity of the 
Cu/Zn superoxide dismutase is higher than in absence of PrPC. The latter condition is 
characterized by high Mn superoxide dismutase activity [65]. Experiments with 
recombinant chicken and mouse PrPC, as well as immunoprecipitated PrPC, have shown a 
PrPC-dependent SOD activity that was abolished by deletion of the octapeptide-repeat 
region. This has suggested an enzymic function for PrPC, dependent on copper intake and 
consistent with its cellular distribution [66]. However this issue is very controversial. 
[67,68]. 
Mithocondria are involved in both oxidative stress and the induction of apoptosis. Studies 
in scrapie-infected hamsters have reported a decreased activity of Mn-SOD compared to 
controls, possibly ascribable to an increasing oxidative stress in the mitochondria of the 
infected brain. This hypothesis is supported by a high level of lipid peroxidation and low 
levels of ATPase and cytochrome c oxidase activity in the infected cerebral mitochondria 
[69]. In an inbred line of mice, in tissues that normally express PrP at moderate-to-high 
levels, ablation of PrPC resulted in reduced mitochondrial numbers, unusual mitochondrial 
morphology, and elevated levels of mitochondrial manganese-dependent superoxide 
dismutase antioxidant enzyme [70]. 
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4.3. PrPC at synapses 
The putative role of PrPC in neuronal cellular communication derives from its localization 
both in the pre- [71] and postsynaptic structures [72]. Using a sensitive post-embedding 
immunogold electron microscopy method in the brain of variant Creutzfeldt-Jakob disease 
patients, PrP-gold labeling has been found predominantly in the presynaptic domain of 
synapses [73,74]. This suggests that synaptic pathology is a major event in spongiform 
encephalopathy, with loss of GABAergic neurons as the first detectable neuropathological 
change. Presynaptic bouton loss (an alteration accompanied by abnormally aggregated 
vesicles) is also observed, but only at the terminal stage of disease. This is associated with 
a significant decrease in the stimulated [3H]-GABA release from synaptosomes and with 
the accumulationof PrPSc [75]. Alterations may also be attributed to PrPC loss of function, 
since hippocampal slices from PrP-null mice have weakened GABA receptor-mediated fast 
inhibition and impaired long-term potentiation [76]. The circadian rythm and sleep 
homeostasis alteration reported in PrPC-null mice may also be related to synaptic 
dysfunction [77] and impaired hippocampal-dependent spatial learning [78]. 
PrPC has also been found in the neuromuscular junction, namely enriched in subsynaptic 
endosomes [79]. In a mouse phrenic-diaphragm preparation, nanomolar concentrations of 
PrPC  induce a very striking potentiation of the acetylcholine release. The effect was mainly 
pre-synaptic with an increased amplitude of the miniature end-plate currents, probably 
calcium dependent [80]. 
Taken together, these data suggest that PrPC modulates neuronal excitability and synaptic 
activity, which probably forms the neural basis for some of the systemic brain functions 
attributed to PrPC. 
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4.4. Neurite outgrowth 
Mounting evidence indicates that PrPC may act as a recognition molecule or as an adhesion 
molecule. NCAM, the 67-kDa laminin receptor (LR), the 37-kDa laminin receptor 
precursor (LRP) and the extracellular matrix glycoprotrein laminin are believed to be 
interactors of PrPC [81], [82,83], [84]. 
Since these molecules play pivotal roles in cell proliferation, neuronal cell survival, and 
differentiation, it has been proposed that the specific interaction between PrPC and some of 
these molecules could have different consequences for neurite outgrowth, neuronal cell 
survival, and differentiation via some signaling transduction pathways including p59Fyn 
kinase, cAmp/protein kinase A (PKA), protein kinase C (PKC) and MAP kinase 
activation[85], [86]. Both cis and trans interactions between NCAM at the neuronal cell 
surface and PrPC promote recruitment of NCAM to lipid rafts, and thus regulate activation 
of fyn kinase, an enzyme involved in NCAM-mediated signaling. Cis and trans interactions 
between NCAM and PrP promote neurite outgrowth. When these interactions are disrupted 
in NCAM-deficient and PrP-deficient neurons or by PrP antibodies, NCAM/PrP-dependent 
neurite outgrowth is arrested. This indicates that PrP is involved in nervous system 
development  and cooperates with NCAM as a signaling receptor. 
Loss- and gain-of-function experiments have shown that PrPC levels correlate with 
differentiation of multipotent neural precursors into mature neurons in vitro. They have 
also shown that PrPC levels positively influence neuronal cellular differentiation in a dose-
dependent manner. PrPC also increases cellular proliferation in vivo. In the subventricular 
zone of the olfactory bulbs (SVZ), PrPC overexpresser mice have more proliferating cells 
compared with WT or knock-out mice. In the hippocampal dentate gyrus (DG), PrPC 
overexpressor and WT mice have more proliferating cells compared with knock-out mice, 
indicating that PrPC plays an important role in neurogenesis and differentiation [87]. 
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5. Molecular mechanisms mediating PrPC function 
PrPC interacts with different partners, hence it relates to a variety of signaling pathways. 
 
5.1. Signaling  
Like the other raft-associated proteins, PrPC may be involved in different signaling 
pathways. Experiments in the 1C11 cell system aimed at studying PrPC in relation to the 
onset of neuronal cellular functions and within an integrated neuronal context have shown 
that coupling of PrPC with the tyrosine kinase Fyn is closely related to the maturation of the 
cells in a caveolin-dependent manner [88]. This finding suggests that caveolin mediates the 
signaling triggered by engagement of PrPC in cells that express both proteins. This process 
may thus require an intermediate component. NCAM, whose engagement induces 
phosphorylation of Fyn, is a candidate PrPC-binding transmembrane signaling protein [89]. 
Biochemical and co-immunoprecipitation experiments have found that DRMs from growth 
cones show different NCAM species and that caveolae segregate from phosphorylated Fyn 
[90]. 
It has been hypothesized that the cross-linking of PrPC to Fyn promotes a rearrangement of 
membrane rafts through lateral movement of distinct domains, and that the interaction with 
NCAM may couple PrPC with Fyn on the cytoplasmatic leaflet of the plasma membrane 
[91]. 
 
Experiments with PrPC-binding peptide in retinal explants from neonatal rats or mice have 
shown that PrPC activates both cAMP/protein kinase A (PKA) and ERK pathways. It also 
partially prevents cell death induced by anisomycin (ANI) in explants from WT rodents, 
but not in those from PrPC-null mice. This result indicates that PrPC may function as a 
trophic receptor, whose activation leads to a neuroprotective state [92]. In support of this 
hypothesis, cell surface binding and pull-down experiments have shown that recPrP binds 
to cellular STI1 (stress-inducible protein 1), and co-immunoprecipitation assays strongly 
suggest that both proteins are associated in vivo. Moreover, PrPC interaction with STI1 
induces neuroprotective signals that rescue cells from apoptosis [21]. Protection of 
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hippocampal neurons in culture by hop/STI1 can also be blocked by a PKA inhibitor [85]. 
Interestingly, in PrP knock-out retinal explants from neonatal rats or mice the basal levels 
of both cAMP and PKA are higher than in PrP WT samples, arguing for a compensatory 
effect for PrPC ablation [93]. The induction of neurite outgrowth and neuronal cell survival 
by trans-interacting PrPC in cerebellar granule cells can be blocked by a PKA inhibitor. Yet  
it has no effect on axon outgrowth induced by recPrP upon embryonic hippocampal 
neurons in culture [94]. 
In 1C115-HT cells the antibody-mediated ligation of PrPC, concomitant with agonist 
stimulation of 5-HT receptors, disturbs the couplings of all three serotoninergic receptors 
present on 1C115-HT cells by affecting the potency or dynamics of G-protein activation by 
agonist-bound serotonergic receptors. The PrPC-dependent modulation of 5-HT receptor 
couplings critically involves a PrPC-caveolin platform implemented on the neurites of 
1C115-HT cells during differentiation [95]. Despite this evidence, the adenylyl cyclase 
family includes both transmembrane and soluble forms, which can be regulated by other 
factors such as calcium and calmodulin [96]. PrPC-dependent activation of the cAMP-PKA 
pathway may be mediated by either voltage-gated or store-operated calcium-channels at the 
plasma membrane. Alternatively, PrPC may modulate this pathway interacting with 
transmembrane forms of adenylyl cyclase. 
 
PrPC expression has also been linked to activation of the ERK pathway. In the neuroblastic 
layer of the developing retina, a peptide that binds residues 113–128 of the mouse (114–
129 human) PrPC (the PrR peptide) induces a neuroprotective response in vitro, activating 
both the cAMP/PKA and the ERK signaling pathways. Interestingly, inhibition of PKA 
activity blocked the effect of the PrR peptide, whereas inhibition of the ERK pathway 
potentiated the PrPC-mediated neuroprotection [92]. In PrP-null retinae and in hippocampal 
neurons, basal ERK phosphorylation has been found to be higher than in the WT controls, 
hinting at a compensatory response for the ablation of the Prnp gene. Since ERK 
phosphorylation can be prevented by blocking the activity of NADPH oxidase, which also 
follows PrPC cross-linking, the production of reactive oxygen species (ROS) may be an 
intermediate step in the PrPC activation of ERK. In both serotoninergic and noradrenergic 
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1C11-derived cells, recruitment of the tyrosine kinase Fyn appears to be a prerequisite for 
both NADPH oxidase activation and ERK1/2 phosphorylation [97]. The idea of an 
additional NADPH oxidase-independent pathway is drawn from the observation that in the 
differentiated 1C11 derivatives, the pharmacologicals inhibition of NADPH does not 
completely block ERK1/2 phosphorylation. 
The exposure of PrPC fusion proteins in a mouse monocyte/macrophage cell line is 
accompanied by an increase in cellular tyrosine phosphorylation, as a result of activated 
signaling pathways including phosphorylation of ERK(1/2) and Akt kinase [98]. Taken 
toghether these results indicate that the ERK signaling pathway is activated by both the 
recruitment of PrPC at the cell surface and exposure to extracellular PrPC. This activation 
may be secondary to various upstream events. 
In differentiated 1C11 cells, the antibody cross-linking promotes Fyn phosphorylation [99] 
and the inhibition of Fyn by PP2 inhibits, in turn, ERK activation [97]. Adding puri$ed 
recPrP to rat fetal hippocampal neurons in culture influences axon elongation. This effect is 
blocked by inhibitors of protein kinase C (PKC) and of Src kinases, including p59Fyn. On 
the other hand, inhibitors of phosphatidylinositol 3-kinase show only a partial inhibition, 
suggesting that signaling cascades involving these kinases are candidates for transduction 
of recPrP-mediated signals [94]. In contrast, immunofluorescence confocal microscopy 
observations of cerebellar granule cells have established that Fyn with PrPC are present 
within the same cell and are mostly not colocalized [100]. Moreover, adding exogenous 
PrP fusion proteins to monocyte/macrophage cell line P388D-1 — in which a high basal 
phosphorylation level of fyn kinase has been found — does not remarkably change 
phosphorylation level of fyn kinase after stimulation with PrP-Fc. Notably, PrP-Fc resulted 
in phosphorylation of the non-receptor tyrosine-kinase Syk and Pyk2, as well as the adaptor 
protein Cbl [98]. 
Several studies describe the activation of the Protein kinase C (PKC) by PrPC. In membrane 
detergent-resistant fractions, PrP and PKC have been detected in the immunoprecipitate 
obtained with anti-GAP43 or anti-PrP antibody at 4°C [100] and in rat hippocampal 
primary cultures. Inhibitors of protein kinase C (PKC) have blocked the effect of recPrP on 
axon elongation [94]. Consistent with a possible role for PrPC in immune function, PrP 
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knock-out splenocytes have displayed defects in upstream or downstream mechanism(s) 
that modulate PKC"/% phosphorylation. This in turn may affect PrP capacity to regulate 
splenocyte mitosis [101]. However the link between PrPC and PKC is not fully clarified. 
The relationship between PrPC expression and induction of phosphatidylinositol 3-kinase 
(PI 3-kinase) activity has also been investigated [100]. This kinase plays a pivotal role in 
neuronal cell survival and apoptosis and, like PrPC, it is also associated with lipid 
microdomains. Both mouse neuroblastoma N2a cells and immortalized murine 
hippocampal neuronal cell lines expressing WT PrPC had significantly higher PI 3-kinase 
activity levels than their respective controls. Moreover, PI 3-kinase activity was found to be 
elevated in brain lysates from WT mice, as compared to PrP-knockout mice. Recruitment 
of PI 3-kinase by PrPC was shown to contribute to cellular survival toward oxidative stress 
by using 3-morpholinosydnonimine (SIN-1) and serum deprivation. Both PI 3-kinase 
activation and cytoprotection by PrPC appeared to rely on copper binding to the N-terminal 
octapeptide of PrPC [102]. In other studies, PrPC deletion impaired the antiapoptotic 
PI3K/Akt pathway by reducing postischemic phospho-Akt expression, followed by 
enhanced postischemic caspase-3 activation. PrPC deletion also aggravated neuronal injury 
after both transient and permanent cerebral ischemia in vivo [103]. Nonetheless, authors did 
not rule out the possibility that additional pathways (e.g., MAPK/ERK19) or molecular 
events mediating necrotic cell death (e.g., poly(ADP-ribose)polymerase [PARP] activation) 
may also contribute to enhanced ischemic brain injury in absence of PrPC. 
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5.2. Trafficking of PrPC 
PrPC is expressed on the cell surface and endocytosis is hypothesized to function as a way 
to control its related cellular signaling. 
 
5.2.1. PrPC endocytosis  
Like the other GPI-anchored proteins, in PrPC the lack of intracellularly oriented amino 
acid sequences indicates that it cannot interact directly with adaptor proteins necessary for 
clathrin-mediated endocytosis. However, the presence of GPI-anchored proteins in lipid 
rafts may be important for their endocytosis [104]. In particular, some GPI-anchored 
proteins are colocalized with caveolae or caveolin-1. Caveolae are markers of ‘flask-
shaped’ or ‘omega-shaped’ membrane invaginations, which present no clathrin coat !"It has 
been proposed that localization of GPI-anchored proteins at caveolae or caveolae-like 
domains may be triggered by antibody cross-linking [105]. 
A number of studies have detected the expression of PrPC or PrPSc from cultured cells in 
caveolae-like organelles, based on their resistance to solubilization by certain detergents at 
4°C, isolation by flotation in sucrose gradients and also copurification with markers for 
DRMs [106,107]. The observation that PrPC is found in DRMs and that perturbation of 
cholesterol synthesis or drugs that bind to cholesterol changes PrPC trafficking, it was 
suggested that, similarly to some GPI-anchored proteins, mammalian PrPC and PrPSc might 
be internalized independently of clathrin [106]. However, many of the drugs used for 
determining raft association have variable effects on cellular cholesterol levels. Therefore, 
it is still unclear whether caveolae-mediated endocytosis is involved in PrPC trafficking in 
neuronal cells. Interestingly, chPrP, a chicken homologue of mammalian PrPC, has been 
shown to constitutively cycle between the cell surface and an endocytic compartment, with 
a transit time of approximately 60 min in cultured neuroblastoma cells, and its endocytosis 
is mediated by clathrin-coated pits [11]. The internalization of chPrP was observed to drop  
by 70% after neuroblastoma cells incubation in hypertonic medium — a treatment that 
inhibits endocytosis by disrupting clathrin lattices. This led to the hypothesis that, unlike 
other GPI-anchored proteins, PrPC is internalized by clathrin-coated pits [11]. In addition, 
in primary cultured neurons and in the N2a neural cell line, PrPC has been shown to be 
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rapidly and constitutively endocytosed. While still on the cell surface, PrPC leaves lipid 
‘raft’ domains to enter non-raft membrane, from which it enters coated pits [13]. 
The use of GFP–tagged PrPC to examine PrP traf$cking [108] (PrPc on the road: traf$cking 
of the cellular prion protein. Marco A. M. Prado, 2004) has suggested that clathrin- and 
dynamin-mediated endocytosis is one of the main pathways for the internalization of the 
PrPC, although clathrin-independent mechanisms may also participate in its internalization. 
The same experimental paradigm has also shown that the protein is found in both the Golgi 
and the recycling endosomial compartment. Perturbation of endocytosis with a dynamin I-
K44A dominant-negative mutant has altered the steady-state distribution of the GFP-PrPC, 
leading to the accumulation of fluorescence in unfissioned endocytic intermediates [109]. 
Further immunoelectron microscopy experiments have shown that, in neurons, PrPC is 
present in endosomes containing transferrin [13]. Together, these results suggest that at 
least one of the pathways for PrPC internalization involves classical endosomes. In contrast, 
cryoimmunogold electron microscopy studies on the localization and internalization of 
PrPC in CHO cells have shown a caveolae-dependent endocytic pathway that was not 
observed for other GPI-anchored proteins [10]. These results indicate that there are 
different routes for the internalization of PrPC (clathrin- or non-clathrin-mediated 
endocytosis) although increasing evidence supports the importance of classical endosomal 
organelles containing distinct Rab proteins. 
 
5.2.1.1. Copper-dependent PrPC endocytosis 
Over the past few years, it has become clear that the PrP binds copper in vivo, and the 
interaction between PrPC and copper requires the highly conserved, N-terminal octarepeat 
domain. In 1997 Brown et al., showed that brain extracts from PrP knock-out mice have 
lower copper content than WT mice, and they also exhibit reduced copper metalloprotein 
activity [110]. However this result was not further confirmed. Indeed, in 2000 Waggoner 
and collaborators have demonstrated that brain Copper content and Cuproenzyme activity 
do not vary with PrPC expression levels leading to the suggestion that PrPC is not the 
primary carrier responsible for entry of copper into the brain via the blood-brain or blood-
CSF barriers or for uptake of the metal into neurons from the extracellular space [67]. 
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Experiments with GFP-PrPC have shown that PrPC is internalized in response to Cu2+, and it 
accumulates in the perinuclear region of organelles. The internalization of GFP-PrPC 
appears to be specific to the interaction of Cu2+ with GFP-PrPC, as the N-terminal mutants 
are not internalized under the same condition [111]. However, it is still unclear whether the 
steps involved in Cu2+-induced PrPC endocytosis are the same for constitutive 
internalization of the protein. 
 
5.3 PrPC and cell adhesion 
Different studies have highlighted the function of PrPC as adhesion or recognition 
molecule. In cultured hippocampal neurons, PrPC promotes survival by mediating their 
adhesion and it triggers their phenotypic modifications by interacting with the extracellular 
matrix glycoprotein laminin (LN) [112]. In the PC-12 cell line, the PrPC–LN interaction is 
involved in the neuritogenesis induced by NGF plus LN and the binding site resides in a 
carboxy-terminal decapeptide from the (-1 LN chain [82].  
PrPC has also been shown to co-localize with the 37-kDa laminin receptor precursor (LRP) 
and with its mature 67-kDa form termed high-affinity laminin receptor (LR) on the plasma 
membrane fractions of N2a cells [83]. In situ crosslinking of N2a cells has allowed for the 
identification of the neural cell adhesion molecule (N-CAM) as PrPC-interacting protein 
[84]. This latter is recruited by PrPC into lipid rafts, activating Fyn kinase and promoting 
cell adhesion and neurite outgrowth [89] (Fig. 5). 
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Figure 5. PrPC interaction with neural cell adhesion molecule (NCAM). (a) Schematic 
illustration of the interaction between PrPC and NCAM leading to the activation of Fyn. (b) 
PrPC partially colocalizes with NCAM along neurites and in growth cones (arrows) of 
cultured hippocampal neurons. (Modified from [113]). 
 
PrPC has also been involved in the proteolysis of the contactin-associated protein (Caspr). 
PrP inhibits the extracellular matrix Reelin-mediated shedding of Caspr from the cell 
surface, thereby increasing surface levels of Caspr and potentiating the inhibitory effect of 
Caspr on neurite outgrowth [114].  
Further evidence for a role of PrPC in the modulation of cell adhesion via signaling derives 
from studies in zebrafish embryos [115]. Zebrafish contain duplicated PrP genes, PrP-1 
and -2, which play different roles during distinct developmental stages. PrP-1 and E-
cadherin interact genetically to control distinct cell morphogenetic movements required for 
zebrafish gastrulation. In this model, also the accumulation of PrP at cell contact sites was 
shown to be concomitant with the activation of Src-related kinases, the recruitment of 
reggie/flotillin microdomains, and the reorganization of the actin cytoskeleton. 
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5.4 Role of PrPC in neuronal excitability  
The synaptic distribution of PrPC in the hippocampus [72] — where many kinds of ion 
channels are concentrated — has led to hypotesize a possible involvement of PrPC in their 
regulation and in neuronal excitability. Hippocampal slices from PrP null mice have 
weakened GABAA ((-aminobutyric acid type A) receptor-mediated fast inhibition and 
impaired long-term potentiation [76]. The neurophysiological evaluation of double 
transgenic mice generated using the Cre–loxP system has showed a significant reduction 
the after hyperpolarization potentials (AHPs) in hippocampal CA1 cells depleted of PrPC. 
This observation has reinforced the idea of a direct role for PrPC in the modulation of 
neuronal excitability [116]. Patch-clamp studies of Ca2+-activated K+ currents in cerebellar 
Purkinje cells in the slice preparation of Prnp0/0 mice have shown a significant correlation 
between PrPC expression in Purkinje cells and the maximal amplitude of TEA-insensitive 
Ca2+-activated K+ currents. Moreover they have shown reduced current amplitudes in 
Prnp0/0 mice and a rescue of the phenotype in transgenic mice where PrPC had been 
reintroduced [117]. Animals lacking PrPC expression have resulted more susceptible to 
seizures induced by various convulsant agents than WT controls, probably as 
hyperexcitability leads to excitotoxicity [118]. This observation might be linked to the 
aberrant activation of the NMDA subtype of ionotropic glutamate receptors (NMDARs) 
observed in PrP knock-out mice [119]. Coimmunoprecipitations from PrPC WT mouse 
hippocampal homogenates of PrPC and the NR2D subunits of the NMDARs have shown the 
close association of these two proteins. This interaction may serve to silence the activities 
of NR2D-containing NMDARs [119]. 
PrPC-deficient mice have also been shown to have an increased sensitivity to kainate-
induced seizures in vivo and in vitro in organotypic slices. This sensitivity is cell-specific 
because interference experiments to abolish PrPC expression have increased susceptibility 
to kainate in PrPC-expressing cells [120]. Other studies have described the association 
between PrPC and the group I metabotropic glutamate receptors (mGluR1 or mGluR5), 
which is able to transduce cellular signals on Laminin (1 peptide binding to PrPC [121]. 
Patch-clamping experiments to directly test for a connection between PrPC molecules 
carrying neurotoxic deletions in the central region ('CR PrP) and ion channel activity have 
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shown the generation of spontaneous currents when expressed in a variety of different cell 
types [122]. Remarkably, similar currents were induced by several different point 
mutations in the central region, which are linked to familial prion diseases in humans. This 
suggests that common structural domains control both the functional activity of PrPC and 
its ability to be converted to PrPSc [123]. 
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6. PrPC and Reelin 
The expression of PrPC on the cell membrane makes it a potential candidate for a ligand 
uptake, cell adhesion and recognition molecule or a membrane-signaling molecule. PrPC 
has been shown to interact with the contactin-associated protein (Caspr). This adhesion 
molecule is required for the formation of axoglial paranodal junctions surrounding the 
nodes of Ranvier in myelinated axons [124]. PrPC prevents Caspr from shedding at the cell 
surface and result in an inhibitory modulation of neurite outgrowth in neurons, which is 
counterbalanced by the proteolytic activity of Reelin [114]. 
 
6.1. Reelin 
6.1.1. Reelin structure and processing 
Reelin is a large (>400 kDa) extracellular glycoprotein, which is secreted by several 
neurons, particularly, in the embryonic cortex, by Cajal–Retzius cells. Defective Reelin is 
the cause of the reeler brain malformation in mice [125,126] and of a peculiar type of 
lissencephaly in man [127]. In Reeler mice, neurons are generated in ventricular zones 
(VZ) and initially migrate as in normal animals. However, unlike normal cells, Reeler 
neurons form defective architectonic patterns. Whereas normal cortical neurons form a 
dense, radially and laminarly organized cortical plate (CP) in which maturation proceeds 
from inside to outside, Reeler neurons form a loose CP in which they are oriented obliquely 
and the gradient of maturation is almost inverted. 
Reelin gene (Reln) is localized to chromosome 7 in man [128]. On SDS-PAGE, Reelin 
appears as several protein bands, ranging from 410 to 330, 180 kDa, and several smaller 
fragments [129],[130,131]. Figure 6 schematizes the domain structure organization of 
Reelin. 
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Figure 6. Modular structure of the Reelin molecule. Reelin contains a cleavable signal 
peptide at the amino terminus, followed by a region of similarity to F-spondin, a secreted 
protein produced by floor plate cells that controls cell migration and neurite outgrowth. The 
most striking feature of Reelin is the presence of eight internal repeats comprising aa 350–
390. These so-called Reelin repeats contain two related subdomains, A and B, separated by 
a stretch of 30 amino acids harbouring an epidermal growth factor (EGF)-like motif. A 
region rich in arginine residues at the carboxy terminus is required for secretion. Modified 
from [132]. 
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Human Reelin  is 94.8% identical to the mouse protein at the amino acid level, indicating 
strong functional conservation [128].  It is a modular protein composed of a signal 
sequence, an F-spondin-like region, nine sequentially concatenated repeat units of ~380 
amino acids, and a C-terminal basic tail region. Each of the eight Reelin repeats contains a 
central epidermal growth factor (EGF) module flanked by two homologous subrepeats of 
150-190 amino acids. The EGF-like module is ubiquitous among extracellular proteins, but 
the two subrepeats are unique to Reelin and do not show any sequence similarity to other 
protein families. A Reelin fragment composed of central repeats 3–6 recapitulates most of 
its functions in cortical development [133,134]. Reelin is cleaved in vivo at two sites 
approximately located between repeats 2 and 3 and between repeats 6 and 7. This process 
did not occur in Relnrl-Orl mutant mice in which Reelin is not secreted. It can also be 
prevented in explant cultures by brefeldin treatment, thus suggesting that this process takes 
place extracellularly or in a postendoplasmic reticulum compartment. Further Reelin 
cleavage can be inhibited by zinc chelators known to inhibit metalloproteinases, and has 
been shown to be insensitive to inhibitors of matrixins, neprilysin, meprin, and peptidyl 
dipeptidase A, suggesting that the processing enzyme belongs to a different enzyme family 
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[135]. An epitope known as the CR-50 is localized near the N-terminus [136] and is 
composed of aa 230–346 of Reelin glycoprotein. This epitope is essential for Reelin–Reelin 
electrostatic interactions that produce a soluble string-like homopolymer, composed of up 
to 40 or more regularly repeated monomers, which form in vivo. Reelin mutants lacking the 
CR-50 epitope fail to form homopolymers and are therefore unable to transduce the Reelin 
signal [137]. In vitro, after purification, Reelin undergoes rapid self-degradation and the 
major 140-kDa fragment has an enzymatical activity, since it has been shown to bind the 
FP-Peg-biotin stronger than full-length Reelin. These data argue that the proteolytic 
processing of Reelin is functionally important, and that full activity of Reelin might require 
degradation of the 400-kDa full-length precursor to generate smaller, more active isoforms. 
The observation that fibronectin and laminin are rapidly degraded by purified Reelin and 
that fibronectin degradation is inhibited by inhibitors of serine proteases and by 
monoclonal antibody CR-50 suggests that Reelin has a specific serine protease activity. 
The proteolytic activity of Reelin on adhesion molecules of the extracellular matrix and/or 
receptors on neurons may explain how Reelin regulates neuronal cell migration and 
synaptic plasticity [131]. 
 
6.1.2. Reeler mice 
The reeler mouse is one of the best-known spontaneously occurring mutants in the research 
field of neuroscience. This animal model has been used to understand mammalian brain 
development. The reeler mutant mouse was first described over 50 years ago. It is a 
spontaneously arising mutant that displays behavioral abnormalities such as ataxia, tremor, 
and Reelin gaits, which may be caused by cerebellar malformation [138]. In these mutants 
the migration of many neurons is abnormal, resulting in disrupted cellular organization of 
brain laminated structures such as cerebellum, cortex and hippocampus [139]. Differently 
from the cerebellum of a normal mouse, the Reeler one is smaller, its surface is occupied 
by a thin, quasi-normal cerebellar cells with many malpositioned Purkinje cells, which 
aggregate into a central cellular mass. The granular cells in the Reeler form a layer beneath 
the molecular one, with a lower cell density than in the normal counterpart [138]. In Reeler 
mice, the distinct laminar structure of the hippocampus proper (i.e. Ammon’s horn) and 
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dentate gyrus (DG) is disrupted (Fig. 7). The radial glial scaffold, which is presumed to be 
important for neuronal cell migration, is not present in Reeler hippocampus [140]. In the 
dentate gyrus of the adult Reeler, the number of newly generated neurons is lower than in 
the WT controls, whereas GFAP-positive astrocytes increase, suggesting that the balance of 
neurogenesis and gliogenesis is regulated by Reelin in the adult brain [141]. 
At embryonic stage (E) E12.5 and E14.5, prominent expression of Reelin by Cajal-Retzius 
cells is detectable just beneath the pial surface of the cerebral cortex corresponding to the 
marginal zone or the future layer I [142]. Autoradiographic analysis of brains that received 
tritiated thymidine at speci$c stages during development can reveal the temporal and 
spatial assembly of cells. This approach has revealed that cortical neurons in the mouse are 
generated between E10 to E18 and that the 6 layers of the cerebral cortex assemble in an 
inside-out sequence [143]. These studies have shown that, in addition to morphological and 
physiological characteristics, neurons positioned within speci$c cortical layers also share a 
common birth date. The Reeler cerebral cortex violates this fundamental plan of cortical 
assembly [144]. Layer I is not discernible in the mutant, and the position of cells 
comprising other layers is relatively inverted. Importantly, all major morphological cell 
classes are present in the Reeler cortex, and cohorts of neurons comprising speci$c layers 
are generated on schedule [145]. The neuronal classes in Reeler cortex fail to align in an 
inside-out fashion like their counterparts in the normal cortex. In Reeler, neurons born 
relatively late during corticogenesis reside in deep layers beneath the older neurons [145]. 
These comparative studies have shown that the Reeler mutation affects the positioning of 
neurons within speci$c layers (Fig. 8). 
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Figure 7. Horizontal sections through the hippocampal formation show 
cytoarchitecture of the normal (A) and Reeler (B) mice. A, B: The distinct laminar 
structure of the hippocampus proper (i.e. Ammon’s horn) and dentate gyrus (DG) of the 
normal mouse (A) is disrupted in those of the Reeler mouse (B). Modified from [138]. 
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Figure 8. Retrogradely labeled corticospinal tract (CST) neurons in the motor cortex 
of normal (A) and Reeler (B) mice A, B: CST neurons in the motor cortex are 
retrogradely labeled by injecting horseradish peroxidase (HRP) in the spinal cord 2 days 
before death. HRP-labeled neurons accumulate in layer V of the normal cortex (A), 
whereas they are scattered throughout the radial axis of the reeler cortex (B). Modified 
from [138]. 
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6.1.3. The molecular basis of Reelin signal transduction 
Using genetic and biochemical approaches, several studies by different laboratories have 
shown the existence of a linear signalling pathway for Reelin [146,147]. Reelin signals 
through its binding to the very-low-density lipoprotein receptor (VLDLR) and APOE 
receptor 2 (ApoER2) which in turn activate the cytoplasmic adapter protein disabled 1 
(DAB1) by tyrosine phosphorylation (Fig.9). 
 
!
Figure 9. Schematic representation of the Reelin-signaling pathway in neurons. The 
high affinity Reelin binding to the two lipoprotein receptors, ApoER2 and VLDLR, 
induces the feed-forward activation of Dab1, a cytoplasmatic interactor protein that 
specifically recognizes the NPxY motifs present in the cytoplasmatic tails of both 
receptors. The clustering of Dab1 activates SRC family tyrosine kinases (SFKs), which 
enhance the phosphorylation levels of Dab1 and, in turn, promote the activation of 
phosphatidylinositol-3-kinase (PI3K) and subsequently protein kinase B (PKB). PKB 
activation inhibits the activity of glycogensynthase kinase 3% (GSK3%). As a result, 
phosphorylation of ) is reduced, promoting microtubule stability. ApoER2 associates with 
postsynaptic density protein 95 (PSD-95), an abundant scaffolding protein in the PSD, 
through an alternatively spliced exon. This interaction is crucial for the coupling of the 
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Reelin signaling complex to the NMDA (Nmethyl-d-aspartate) receptor (NMDAR). 
Reelin-activated SFKs tyrosine phosphorylate the NMDAR on NR2 subunits, resulting in 
the potentiation of NMDAR-mediated Ca2+influx. Elevated intracellular Ca2+ can activate 
the transcription factor cyclic AMP response element binding protein (CREB), thereby 
potentially initiating the expression of genes that are important for synaptic plasticity, 
neurite growth and dendritic spine development. Modified from [148]. 
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Binding to the receptors, Reelin induces Dab1 tyrosine phosphorylation by Src-family 
kinases such as Src and Fyn [149,150]. Phosphorylated Dab1 subsequently interacts with 
other proteins known to be important for the regulation of neuronal cell migration including 
lissencephaly protein 1 [151] and phosphatidylinositol 3-kinase (PI3K) [152]. Activation of 
PI3K leads to further downstream signaling including activation of Akt and alterations in 
glycogen synthase kinase 3ß (GSK3 ß) one of the main kinases that phosphorylates the 
microtubule-stabilizing protein ) (tau) [153]. 
The recruitment of ubiquitin ligases to phosphorylated DAB1 promotes its 
polyubiquitylation and possibly also monoubiquitylation, which could mediate the 
phosphorylation-dependent endocytosis of the entire Reelin signalling complex. The signal 
is terminated with Reelin being targeted to the lysosome and DAB1 being degraded by the 
proteasome, and the receptors recycle back to the membrane [154-156]. 
 
6.1.4. Involvment of the Reelin pathway in synaptic functions 
The principal signalling of Reelin does not act only on microtubules during development, 
but is also used in the synapse to regulate NMDA receptor activity through the 
phosphorylation of intracellular tyrosine residues. During development, Reelin is produced 
in abundance by Cajal–Retzius neurons at the surface of the developing neocortex [157], 
but these cells eventually disappear and Reelin expression is maintained by a subset of 
GABA ((-aminobutyric acid)-containing interneurons that originate from the medial 
ganglionic eminence [158]. Studies with VLDLR and ApoER2 knock-out mice have shown 
that both receptors can bind Reelin with the same affinity and only the lack of both can 
rensemble the Reeler phenotype [147]. Electrophysiological studies in VLDLR- and 
ApoER2 knock-out mice have also shown that not only both receptors must function in 
concert to increase synaptic plasticity in response to Reelin, but also that there is a highly 
regulated physiological function for Reelin in the control of synaptic transmission, memory 
and learning [159]. A physiological role of Reelin-signaling in learning and memory by 
modulating NMDA receptor functions is directly evidenced by the observation that Reelin 
mediates tyrosine phosphorylation of the cytoplasmic domains of the NMDA receptor, 
NR2A or NR2B, and potentiates calcium influx through NMDA receptors in primary WT 
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cortical neurons but not in Dab1 knock-out neurons or in cells in which Reelin binding to 
its receptors is blocked by a receptor antagonist [160]. In particular ApoER2 at the 
synapses seems to be involved in the regulation of the NMDA receptors by tyrosine 
phosphorylation of its cytoplasmatic domain and the coupling of both can occur through 
extracellular as well as intracellualr interactions [161], [160,162]. The presence of amino 
acids encoded by an exon in the intracellular domain of ApoER2 has been reported to 
enhance LTP.  
The poor performance in learning and memory tasks by mice constitutively lacking the 
exon reinforces the hypothesis that the alternative splicing of ApoER2 can control 
the modulation of NMDA receptor activity, synaptic neurotransmission and memory by 
Reelin [161]. 
 
6.1.5. Involvement of the Reelin pathway in neuropathology 
The Reelin signalling pathway has been related to some neurological and neuropsychiatric 
disorders that afflict the adult brain. This hypothesis is supported by the prominent role for 
Reelin and APOE receptors in the control of synaptic functions and plasticity. The 
reduction of RELN mRNA in postmortem brain tissues from schizophrenia patients and in 
bipolar postmortem brain tissues is considered among the most consistent molecular 
findings in these diseases [163]. A decreased expression of Reelin mRNA by hippocampal 
Cajal–Retzius cells has also been correlated with the extent of migration defects in the 
dentate gyrus of patients with temporal lobe epilepsy. This suggests that Reelin is required 
for normal neuronal lamination in humans, and that deficient Reelin expression may be 
involved in migration defects associated with temporal lobe epilepsy [164]. Reeler mutants 
have also been to shown to have profound sensory defects. They manifest a significant 
reduction in mechanical sensitivity and a pronounced thermal hyperalgesia (increased pain 
sensitivity) compared with control mice, indicating that Reelin-signaling is an essential 
contributor to the normal development of central circuits that underlie nociceptive 
processing and pain [165]. 
Furthermore, Reelin expression and processing is altered in several amyloid conditions. In 
particular, alterations in Reelin-mediated signaling have been suggested to contribute to 
neuronal dysfunction associated with Alzheimer's disease (AD). Experiments with aged 
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Reelin-deficient transgenic AD mice have shown an age-related Reelin aggregation and a 
concomitant reduction in Reelin-mediated signaling which plays a proximal role in 
synaptic dysfunction associated with amyloid-beta deposition. This effect is sufficient to 
enhance Tau phosphorylation and tangle formation in the hippocampal formation of those 
mice [166]. 
 
7. PrPC in neurodegeneration 
The conversion of PrPC in the abnormal isoform PrPC is the causative agent of the TSEs 
including Creutzfeldt-Jakob disease (CJD) [167]. According to the seeding-nucleation 
model, during prion propagation in the brain the pre-existing or acquired PrPC oligomers  
catalyze the conversion of PrPC molecules into PrPSc fibrils. Their breakage releases more 
PrPC seeds for the conversion process [168]. However, the means by which prions damage 
the CNS remain unknown. 
The observation that PrPC is a mediator of amyloid-%-oligomer-induced synaptic 
dysfunction has led to hypothesize a connection between prions and AD [23]. However this 
issue is still controversial, since several groups failed to reproduce this finding in vivo or in 
vitro [169-171]. 
As for other protein aggregation diseases, PrPSc oligomers are the major component of 
infectious prion particles. The intracerebral inoculation of prions in PrP-deficient mice 
previously grafted with neural tissue overexpressing PrPC, has shown that the grafts 
accumulate high levels of PrPSc and infectivity, and develop the severe histopathological 
changes characteristic of scrapie [172]. Moreover, substantial amounts of graft-derived 
PrPSc migrated into the host brain. Even 16 months after inoculation no pathological 
changes were seen in PrP-deficient tissue, not even in the immediate vicinity of the grafts. 
Therefore, in addition to being resistant to scrapie infection, brain tissue devoid of PrPC is 
not damaged by exogenous PrPSc. This indicates that PrP oligomers and fibrils are not toxic 
per se. 
Considering that PrPC is an extracellular GPI-anchored protein, it is still unclear how it 
transmits signals across the membrane during the infection. Although PrPC seems to 
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interact both with NMDA and GABA receptor subunits, how this interaction might be 
involved in neurodegeneration ([119], [173,174]) is still unknown. It has been hypothesized 
that neurodegeneration might be due to the aberrant regulation of protein biogenesis and 
topology at the endoplasmic reticulum [175]. CtmPrP and cytosolic PrP (cyPrP) have been 
reported to interact with and disrupt the function of Mahogunin (Mgrn), a cytosolic 
ubiquitin ligase whose loss causes spongiform neurodegeneration. In particular, the 
transient or partial exposure of PrP to the cytosol leads to inappropriate Mgrn sequestration 
and this, in turn, contributes to neuronal dysfunction and disease [176]. Some interstitially 
shortened PrPC mutants have been described as highly neurotoxic, thus leading to the 
hypothesis that PrPC may oligomerize and those interstitial deletion mutants of PrPC may 
form transmembrane pores [46]. In particular the expression in transfected cells of PrP '105-
125 can provoke large, spontaneous ionic currents, which are produced by relatively non-
selective, cation-permeable channels or pores in the cell membrane and can be silenced by 
overexpression of WT PrP, as well as by treatment with a sulfated glycosaminoglycan 
[122]. However, these kinds of currents have not been recorded in cultured cerebellar 
granule neurons expressing PrP'105–125, raising the question whether such pores suffice to 
induce cell-autonomous death. 
The intracerebral inoculation of large amounts of prions in PrPC knock-out mice have 
shown that prions can be physiologically cleared in a very efficient manner [39]. Both in 
prion infected cultured mouse neuroblastoma cells (ScN2a) PrPSc [177] and in mouse brain 
the half-life for PrPSc is of about 1.5 days [178]. The prominent clearing mechanism seems 
to be prion phagocytosis. How microglia can possibly recognize prions as edible is 
nevertheless still unclear. The existence of additional clearance mechanisms has been 
postulated in neuroectodermal-infected cells. Indeed, when depleted of PrPC post-infection, 
neurons show a reversal of early prion pathogenesis, which may suggest an ability to clear 
prions [179]. 
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8. Aims of the research 
Although PrPC has been established as an absolute requirement for the prion pathology 
[179], the precise physiological function of PrPC is still an open question.  
To gain more insights in the physiological role of PrPC, we carried out a detailed PrPC 
expression analysis in the neurodevelopmental mouse brain by means of in situ 
hybridization and immunohistochemistry.  
We set out to test whether this pattern of PrPC expression was maintained in other 
mammalian species for which not naturally occurring prion diseases have been reported so 
far. To this end we analyzed the PrPC expression pattern in the metatherian South American 
short-tailed opossum (Monodelphis domestica) (Op). We tested different 
immunofluorescence protocols but none of them apparently work for the detection of PrPC 
in the Op coronal brain section. To overcome this technical issue we mapped the regional 
distribution of PrPC by immunohistoblot. 
The different PrPC distribution in the brain regions of Op compared with mouse finding led 
us to hypothesize a different physiological implication for the expression of PrPC in these 
regions. To test the effect of PrPC ablation in the hippocampus we decided to use PrPC 
knock-out mice. In particular we tried to understand how PrPC may contribute to the 
normal physiological function of the CNS studying a possible functional connection 
between PrPC and the Reelin-signaling pathway in the neonatal mouse hippocampus 
! %'!
 
 
Chapter Two 
!
MATERIALS AND METHODS 
2.1. Animals 
All experiments were carried out in accordance with European regulations [European 
Community Council Directive, November 24, 1986 (86/609/EEC)] and were approved by 
the local veterinary service authority. FVB WT, and FVB Prnp0/0 mice [180] were used in 
the experiments. Animals were obtained from the colony maintained at the animal house 
facility of the University of Trieste, Italy. Animals were staged by systematic daily 
inspection of the colony for newborn litters. P0 corresponds to the day of birth [181]. Each 
experiment was performed at least in triplicate. Mice and Op pups were decapitated. Mice 
(at P30) and Op adults (at P45, P50, and P75) were killed by cervical dislocation. For 
histoblotting, brains were rapidly harvested, immediately covered in powdered dry ice and 
included in the embedding medium OCT (Optimal Cutting Temperature). 
 
2.2. Histology 
CNS specimens were fixed in 4% paraformaldehyde-PBS overnight at 4°C, cryoprotected 
in 30% sucrose-PBS and cut coronally at 20 µm. Cryosections were mounted on Fischer 
SuperFrost Plus slides and subsequently processed for immunohistochemistry. 
 
2.3. Immunohistochemistry 
Slides were thawed at room temperature for one hour. After two washes with PBS 1X-
Triton X100 0.03%, sections were blocked with blocking solution: PBS 1X-Triton X100 
0.03%, normal goat serum (NGS) 10% and bovine serum albumin (BSA) 5% for 1 hour at 
RT. Slides were then incubated with primary antibodies diluted in blocking solution at 4°C. 
After 16 hours they were washed 3 times for 5 minutes with PBS 1X-Triton X100 0.03% 
and then incubated for 1 hour with secondary antibodies, diluted in blocking solution. After 
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3 washes of 5 minutes each, the nuclei were stained with DAPI diluted 1:1000 in PBS1X. 
Slides were then extensively washed with PBS1X, mounted with Vectashield (Vector 
Laboratories, Burlingame, CA), and analyzed under Leica fluorescence microscope. All 
data are representative of at least three independent experiments. The same exposure times 
were used for acquiring images from both WT and Prnp knock-out brain slices. Images 
were not modified other than to balance brightness and contrast with GIMP software (see 
section 2.6.7). 
 
2.3.1. Antibodies for immunofluorescence 
The following antibodies were used: 1:400 Anti-Reelin, a.a 164-496 mReelin, clone G10 
(MAB5364, Millipore), recombinant anti-PrPC humanized (HuM) Fab D18 antibody was 
purchased from InPro Biotechnology (S (South San Francisco, CA; ABR-0D18) was used 
to a final concentration of 2 µg/mL. 
 
2.4. Nissl staining 
Twenty-micrometer fixed frozen cryostat sections, mounted on slides, were air-dried for 60 
minutes, stained in 0.1% cresyl violet (Sigma at 40°C for 7 minutes) and then rinsed in 
distilled water. Slides were soaked in 95% ethyl alcohol for 5 minutes and dehydrated in 
100% alcohol for 5 minutes. Before mounting on glass slides with resin medium (Eukitt, 
Bio-Optica) slides were cleared twice in xylene for 5 minutes. 
 
2.5. In situ hybridization 
Twenty-µm-thick cryosections were cut and collected on slides (Menzel Gläser SuperFrost 
Plus) and then stored at -80°C. Sections were dried at room temperature for 2 hours and 
fixed in 4% PFA in PBS 1X at room temperature for 10 minutes, washed in PBS 1X, 
treated with 18 mg/mL Proteinase K (Roche, Nutley, NJ) at 30°C for 15 minutes, washed 
in glycine 4 mg/mL, PBS 1X, and fixed once more in 4% PFA-PBS1X for 10 minutes, 
washed, incubated in 0.1 M thriethanolamine pH 8.0 with acetic anhydride (0.03%), and 
washed again. Slides were then dried at room temperature and hybridized overnight at 
55°C with 1.5 µg/mL digoxigenin (DIG)-labeled probe in hybridization solution: 50% 
formamide, salts10X pH 7.2 [NaCl 3M, Tris HCl 0.1M, NaH2PO4 0.1M, 2% Ficoll 400 
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(Sigma), 2% polyvinyl pyrrolidone (Sigma)], DTT 2M (Sigma) in 10 mM sodium acetate 
pH 5.2, polyadenilic acid (Sigma) 10 mg/mL, ribonucleic acid (Sigma) 9.2 mg/mL, transfer 
type x–SA (Sigma) 7 mg/mL, 10% dextran sulfate (Sigma). After hybridization, slides 
were washed in 5X SSC-%-mercaptoethanol at room temperature for 30 minutes. Then they 
were washed in 50% formamide-1X SSC-%-mercaptoethanol at 65°C for 30 minutes, 
several times in the NTE solution (5M NaCl, 1M Tris-HCl pH 8.0, 0.5 M EDTA pH 8.0) at 
RT, then in 2X SSC and 0.2X SSC. Slides were put in a humidified chamber with buffer 
B1 (1M Tris-HCl pH 7.5, 5 M NaCl), blocked in HI-FBS (heat-inactivated fetal bovine 
serum)-B1 (10:90) for 60 minutes. Each slide was treated with 1:1,000 anti-DIG (Roche) in 
HI-FBS-B1, covered with a parafilm coverslip, and incubated overnight at 4°C. 
Chromogenic-stained slides were washed several times with buffers B1 and B2 (0.1 M 
Tris-HCl pH 7.5, 0.1 M NaCl, 50 mM MgCl2 pH 9.5) and stained with NBT 3.5 µL 
(Roche)-BCIP 3.5 µL (Roche) in 4 mL B2. After 10 minutes the reaction was observed 
under the microscope and stopped when the transcript signal level was detectable. Slides 
were then washed several times in buffer B1, then in PBS 1X. Slides were mounted with 
one 20 µL drop of PBS 1X 30% glycerol solution and a glass coverslip, sealed with 
enamel, and stored at 4°. 
 
2.5.1. In situ probes cloning and synthesis 
Primer sequences were designed in order to clone the complete 765-basepairs-long coding 
sequence (CDS) of mouse (Mus musculus) Prnp gene in pGEM–T vector (Promega, 
Madison, WI): 5’-TCA TCC CAC GAT CAG GAA GAT GA-3’; 5’-ATG GCG AAC CTT 
GGC TAC TG-3’. Sense and antisense probes were transcribed in vitro with SP6 and T7 
RNA Polymerase (Promega) in the presence of DIGUTP RNA Labeling Mix (Roche), then 
stored at -80°C. The efficiency of labeling was checked and confirmed by Northern blot 
assay, which revealed a single band at the expected base pairs number. 
 
2.6. Histoblots 
The histoblot technique was performed according to protocols by Taraboulos et al. [182] 
with a few modifications. Briefly, uncoated microscope slides (Menzel-Glaser, Madison, 
WI) carrying 20 µm-thick brain serial coronal sections were pressed onto a nitrocellulose 
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membrane wetted in lysis buffer (0.5% sodium deoxycholate, 0.5% Nonidet P-40, 100 mM 
NaCl, 10 mM EDTA, 10 mM Tris-HCl, pH 8.0), incubated for one hour at room 
temperature in 0.1 M NaOH and rinsed 3 times for 1 minute in TBST 1X (50 mM Tris 
HCl, 150 mM NaCl, 0.1% Tween20, pH 7.4). Blots were blocked for 90 minutes in 5% 
non-fat dry milk-TBST 1X. They were incubated overnight at 4°C with the primary 
antibody anti-PrPC humanized Fab D18 [177] purchased from InPro Biotechnology (South 
San Francisco, CA; ABR-0D18) and used at a final concentration of 1 µg/mL. This 
antibody shows high affinity for the region encompassing residues 133 to 152 (in Mo 
numbering), which is highly conserved in different mammals. Membranes were extensively 
washed in TBST 1X and incubated for one hour with secondary antibody diluted in 
blocking mix. The signal was achieved using SIGMAFASTTM 3,3’-Diaminobenzidine 
tablets (Sigma) according to the protocols of the supplier. All data are representative of at 
least three independent experiments. 
 
2.7. Western blotting analysis of PrPC 
Total brains or different brain regions were dissected using a stereomicroscope (Nikon 
SMZ 800) and immediately frozen in liquid nitrogen. Tissues were homogenized in RIPA 
buffer (150 mM NaCl, NP-40 1%, sodium deoxycholate 0.5%, SDS 0.1%, 50 mM Tris, pH 
8.0) with Glass/Teflon Potter Elvehjem homogenizers and spun at 1000 g at 4°C for 5 
minutes. The total protein amount was determined using the BCA Protein Assay Kit 
(Thermo Scientific Pierce). Fifty *g of total protein was then electrophoresed through 
10%–SDS polyacrylamide gels and transferred to nitrocellulose membranes. Membranes 
were probed with monoclonal antibody Fab D18 and developed by enhanced 
chemiluminescence (Amersham ECL Western Blotting Systems, GE Healthcare). Band 
intensity was quantified with the UVI Soft software (UVITEC, Cambridge). 
 
2.8. Immunoprecipitations and Immunoblots of Tyrosine-phosphorylated proteins 
Immunoprecipitations were carried out using the PureProteome Protein A Magnetic Bead 
System (Millipore). Briefly, total brain or P1 mouse hippocampus was homogenized in 
~3% w/v of ice-cold IP Lysis Buffer (Pierce Thermo Scientific) with 2X Protease Inhibitor 
Cocktail (Roche), 2% Phosphatase Inhibitor Cocktail 3 (Sigma), 2% Phosphatase Inhibitor 
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Cocktail 2 (Sigma), 20 mM Na Orthovanadate. Samples were sonicated 3 times for 5 
seconds at 4°C and then left on ice for 30 minutes to allow for the complete lysis. Cellular 
debris and nuclei were removed centrifuging samples at 20’000 g for 20 minutes at 4°C. 
The supernatant was then transferred into a clean tube and the protein concentration was 
determined by BCA (Thermo Scientific Pierce). Two hundred micrograms of total protein 
extracts were then incubated with 2 µg of the capture antibody for 2 hours at 4°C with 
continuous mixing. Fifty microliters of the beads suspension were used for each reaction. 
The pre-formed antibody-antigen complex was added to the beads and then incubated for 2 
hours at 4°C with continuous mixing. The beads were extensively washed with 500 µL of 
0.1% Tween 20-PBS 1X and then resuspended in 30 µL of 2X Sample Buffer (0.1 M 
TrisHCl pH 6.8, 4% SDS, 20% glycerol, 8 M Urea, 0.2 M DTT, 0.004% bromophenol 
blue) and boiled for 10 minutes at 95° C. Samples were then electrophoresed on 10%–SDS 
polyacrylamide gels and transferred to nitrocellulose membranes. To detect Tyrosine-
phosphorylated proteins, the blots were blocked for one hour at room temperature using 
Bløk - PO Noise Cancelling Reagent (Millipore) and incubated for 16 hours at 4°C with the 
primary antibody diluted 1:500 in the blocking mix. To remove the residual primary 
antibody, the membranes were washed 3 times for 5 minutes each in TBST 1X , incubated 
for 45 minutes at room temperature with 1:10’000 Protein A HRP conjugate (Upstate 
(Millipore)) diluted  in blocking mix and then washed several times  in TBST 1X. 
Millipore enhanced chemiluminescence reagent was used to enhance the 
chemiluminescence in Western blot. 
 
2.8.1. Coimmunoprecipitation of ApoER2-PrP 
Immunoprecipitations were carried out using the PureProteome Protein A Magnetic Bead 
System. Briefly, 100 µL of the bead suspension was washed three times with 500 µL of 
PBS. Two hundred micrograms of samples, diluted in PBS, were then added to the beads 
and incubated at room temperature for 30 minutes with constant mixing. The depleted 
samples were collected and incubated with 2 *g of Anti-ApoER2 antibody [EPR3326] 
(ab108208, Abcam) or 2 *g of normal Rabbit IgG (12-370, Millipore) for 4 hours at 4°C 
with constant mixing. The preformed antigen- antibody complex was then incubated with 
50 *l of pre-washed beads for 20 minutes at room-temperature with constant mixing. Beads 
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were then washed 3 times for 5 minutes each with PBS 1X- Tween 0.5% and twice with 
PBS 1X-Tween 0.1%. The washed beads were then resuspended in 30 *l of loading buffer, 
boiled at 95°C for 7 minutes and loaded onto a 10% acrylamide gel.  
 
2.8.2. Antibodies for immunoprecipitation and immunoblot 
The following primary antibodies were used in immunoprecipitation: 1 µg Anti-
phosphotyrosine, clone 4G10 (05-321X, Millipore), 1 µg normal Rabbit IgG (12-370, 
Millipore), 1 µg Dab1 (H-103) (sc-13981, Santa Cruz Biotechnology). The following 
primary antibodies were used in immunoblot: 1:1000 Anti-Reelin, a.a 164-496 mReelin, 
clone G10 (MAB5364, Millipore), 1:500 Dab1 (H-103) (sc-13981, Santa Cruz 
Biotechnology), 1:1000 Anti-phospho-GSK3 (Tyr279/Tyr216), clone 5G-2F (05-413, 
Millipore), 1:1000 Anti-VLDL Receptor antibody [1H10] (ab75591, Abcam), 1:1000 Anti-
ApoER2 antibody [EPR3326] (ab108208, Abcam). 
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Chapter Three 
!
RESULTS 
!
!
The results are presented in chronological order. 
 
3.1. PrPC expression detected throughout the developmental mouse brain 
The overall distribution of PrPC in the mouse brain was analyzed by immunohistochemistry 
in coronal brain sections of E14.5, E18.5, P1, P4, P7, P9, and adult mice. Starting from 
E18.5, the hippocampus showed the highest level of PrPC immunoreactivity, in particular at 
the stratum lacunosum-molecolare (Fig. 10 A-B), a layer rich in synapses from 
hippocampal interneurons and from external inputs, such as the enthorinal cortex [183]. 
Starting from E18.5 a strong and well-defined PrPC immunoreactivity (IR) was also 
observed in white matter structures such as the fimbria (Fi) of the hippocampus (Fig. 10 C-
H) and the stria terminalis (St), the nervous output of the amygdala up to thalamic nuclei  
[184]. 
In the thalamus, PrPC signal was also detected in white matter fiber bundles, such as the 
fornix, the anatomical continuation of the hippocampal fimbria, and in the fasciculus 
retroflexus (or habulointerpeduncolar tract), with a net increase in IR along 
neurodevelopment (Fig. 11 A-H). The specificity of PrPC expression for particular brain 
white matter tracts could be appreciated by the complete lack of PrPC IR of the 
mammillothalamic tract (Fig. 11 A-C). As for the fimbria of the hippocampus and the stria 
terminalis, PrPC IR was first observed at E18.5 and it progressively increased during 
development for the fornix (Fig. 11 I-M) and for the fasciculus retroflexus (Fig. 11 N-P). 
However, in Prnp0/0 mice we did not observe any drammatic alterations in the size or 
morphology of any of these structures. 
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Figure 10. PrPC expression in the hippocampus during development. A-B: At P7 PrPC 
(in red) was detected throughout the hippocampus, and in particularly high levels in the 
stratum lacunosum-molecolare (str l m). A merged image is shown in B (PrPC, in red; 
neurofilament, in green; nuclei signals in blue). C-H: PrPC was specifically and highly 
expressed by the fimbria (Fi) of the hippocampus and the stria terminalis (St) at P7 (C,D). 
The PrPC expression level in Fi and St was high also at embryonic stages (E18.5), and it 
progressively increased during postnatal development: P1 (F), P4 (G), and P7 (H). Scale 
bars: 50 *m. 
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Figure 11. Thalamic expression of PrPC during development. Immunohistochemical 
staining for PrPC (in red; A, C, D–G, I–N) and neurofilament (in green; B,C). A merged 
image is shown in (C). A–C: At P7 PrPC was detected in the thalamus, with abundant and 
specific expression in fornix (A). The specificity of PrPC expression by this structure was 
highlighted by the counterstaining of neurofilaments, which labeled both the 
mammillothalamic tract and the fornix (B). Only the fornix showed colocalization of PrPC 
and neurofilament signals (in yellow; C). D–H: At P7, PrPC expression was detected also 
specifically in the fasciculus retroflexus (or habenulointerpeduncular tract). The fasciculus 
retroflexus expressed PrPC throughout its length, with clear boundaries, highlighted by 
coronal (D–F) or longitudinal (G) PrPC staining. Counterstaining of nuclei (in blue; H) 
highlighted the low number of nuclei in this white matter structure. I–N: Developmental 
PrPC expression by the fornix and the fasciculus retroflexus (Fr). Both structures showed a 
! &&!
progressively increasing level of expression of the protein during development, starting 
from E18.5 (fornix and Fr, respectively; I,L), to P1 (respectively, J,M) until P7 
(respectively, K,N). Scale bars: 50 *m. 
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3.2. Prnp gene expression detected throughout the developmental mouse brain 
The Prnp gene expression was analyzed in the cortex, in the hippocampus and in the 
olfactory bulbs of the developmental mouse brain by in situ hybridization. Between E14.5 
and E16.5 noticeable labeling was detected in brain regions known to have a highly active 
cellular proliferation, namely the ventricular zone (VZ) of the neocortex in the lateral 
ventricles (Fig. 12 A-B) and the neuroepithelia of the third ventricle (IIIv) (Fig.12 I-L). PrP 
mRNA signal was also detected underneath the marginal zone (MZ) in the superficial 
cortical plate (CP), where newborn neurons were. At P1 the signal spanned the entire CP 
(Fig. 12 C-D), whereas at P7 it was mainly restricted to the superficial CP, where the 
youngest neurons were (Fig. 12 E-F). At P7, the signal in the subventricular/ependymal 
zone (SVZ/E) and in the subplate zone (SP) was observed to decrease, whereas it increased 
in the outer layers of the cortex (layers 6-2) (Fig. 12 E-F). At P1 Prnp was detected in the 
SVZ/E layer of the neocortex, in which the neurogenesis persists throughout the animal’s 
adult life, suggesting a possible involvement of PrPC in the cellular proliferation control 
along development [87]. However, a pulse of 5-bromo-2-deoxyuridine (BrdUrd) has shown 
that at E14.5 PrPC is expressed close to the proliferative region but not in the BrdUrd 
positive cells, hence suggesting that PrPC might not be directly involved in cell 
proliferation (Fig. 12 G) 
At P7 a strong Prnp gene expression was detected in the CA1 and in the DG of the 
hippocampus (Fig. 13).  
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Figure 12. Prnp and PrPC expression in the developmental mouse neocortex. A-B: In 
situ hybridization of E14.5 brain coronal sections. A: No positive cells were detected in the 
neocortex area using negative sense probe. B: Positive antisense probe detected Prnp in the 
ventricular zone (VZ). Prnp signal seemed to be underneath the marginal zone (MZ) and in 
the superficial cortical plate (CP). A less intense signal was observed in the subventricular 
zone (SVZ) and in the subplate zone (SP). C-D: In situ hybridization of P1 brain coronal 
section. The antisense probe (D) showed signal for Prnp spanning the entire CP (layer 6-2). 
Negative control sense probe showed specificity of the signal in (C). E-F: Expression 
pattern of Prnp gene in the cortex layers of P7 postnatal stage. The positive signal of Prnp 
(F) was mainly concentrated on the superficial CP, whereas it progressively decreased in 
the subventricular/ependymal zone (SVZ/E) and in the subplate zone (SP). No signal was 
detected with the sense probe (E). (G)!At E14.5 PrPC is not expressed in proliferating cells. 
(Scale bar: 119 µm). 
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Figure 13. Expression of Prnp in the postnatal hippocampus. (A-D) In situ 
hybridization of P7 mouse hippocampal coronal section. (A-B): Prnp signal was detected 
in the CA1 and in the DG cells in the hippocampus. (A) No signal was detected using the 
sense probe. (C-D) Higher magnification of the CA1 pyramidal cells, indicating a clear 
perinuclear staining of Prnp expression (D). (C) No signal was detected with the negative 
sense probe. Scale bars = 50 *m. 
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3.3. PrPC expression in the Op brain is developmentally regulated 
PrPC protein extracts from adult mouse (Mo) PrP knock-out (PrP-/-), PrP WT (PrP+/+) and 
adult Op brains were compared in Western blot (Fig. 14A). The expected di- (~37 kDa), 
mono- (~30 kDa) and un- (~27 kDa) glycosylated forms were detected by Fab D18 
monoclonal antibody both in MoPrP+/+ and Op lanes. No signal was detected in the lane 
loaded with the MoPrP-/- sample, confirming the specificity of the D18 antibody. Although 
all the lanes were loaded with the same amount of total protein, the lower intensity of Op 
PrP signal compared to MoPrP+/+ signal might be due to a lower affinity of the antibody for 
the Op PrP than for the MoPrP+/+. Alternatively, these results might indicate a lower PrPC 
expression in adult Op than in mouse brain.  
Starting from Op P1 to P45, a predominance of the diglycosylated and monoglycosylated 
forms of the protein was observed in Western blot. A minor band corresponding to the 
unglycosylated form of the protein was observed at ~27 kDa (Fig. 14 B). 
The PrPC expression from P10 to P70 was also evaluated in the thalamus, olfactory bulbs, 
cortex and hippocampus (Fig. 14 C). In all these regions an increase in PrPC expression was 
observed until P50. In adulthood the expression of PrPC decreased slightly or remained at 
plateau. At P75, an incremental tendency in PrPC signal was observed in the olfactory 
bulbs. 
 
3.4. Regional expression of PrPC in Op brain coronal sections 
Since PrPC signal was not detectable by immunofluorescence staining performed following 
well-established protocols (Fig.15) described in the literature (Table 1), we investigated the 
regional distribution of PrPC in the Op brain at P15, P20, P37 and P70 by histoblot. After 
the cortico-cerebral neurogenesis was completed [181] at P15 and at P20 strong PrPC 
immunoreactivity (IR) was present in the hippocampus, in the thalamus and in the 
neocortex. In the hippocampus, a signal was observed in the parenchyma but not in the 
pyramidal layer of Ammon’s Horn (CA1-CA3) nor in the granule cell layer of the dentate 
gyrus (DG) (Fig. 16 A-B).  At P37 (Fig. 17 A-B) a dense PrPC signal was observed in gray 
matter structures such as thalamus, cortex and hippocampus. In the latter, PrPC 
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immunostaining was deep in the stratum radiatum and in the stratum oriens. As observed 
at P20, the signal was virtually absent in the pyramidal cells of the CA and in the granule 
cells of the DG. In the hilar region, immunoreactivity (IR) was minimal. PrPC signal was 
detected around the dorsal and the lateral part of the thalamus (Fig. 16 A), encompassing 
structures involved in the communication between thalamus and cortex [185]. 
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Figure 14. Confirmation of antibody specificity and developmental expression of PrPC 
in Op brain. (A) Western blotting of Op, MoPrP+/+, and MoPrP-/- whole brain 
homogenates confirmed the specificity of the PrPC signal. The blot was reprobed with the 
ß-tubulin antibody to demonstrate the equal loading of the samples (50 *g per lane). (B) 
Western blot analysis of equal amounts of total Op brain homogenate (50 *g per lane) at 
different stages of neural development showed a major electrophoretic band at 37 kDa.  
ß-tubulin was used as loading control. (C) Western blotting of indicated Op brain regions at 
different developmental stages showed a relevant change in PrPC expression during 
postnatal development. Each data point represents the mean absorbance ±SEM of 3 females 
from different litters. All the absorbance values were normalized against ß-actin. 
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Table 1: Antigen retrieval methods tested to detect PrPC in the opossum CNS.  
Different antigen retrieval techniques were tested to uncover the PrPC antigenic site in the 
opossum. FabD18 or Saf61 antibodies, previously tested in western blot, did not give a 
specific PrPC signal in immunofluorescence. 
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Figure 15 Immunohistochemical staining of P20 opossum brain shows no specific 
expression of PrPC in the hippocampus. PrPC (in green) and nuclei (blue) were stained, 
and no PrPC immunoreactivity was detected (Bar: 50 µm). 
 
!
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The PrPC signal was also evaluated at P70, after the time of weaning [186]. A low IR was 
observed in white matter structures such as the internal and the external capsule (Fig. 18 
B). In the hippocampus, the strongest signal was detected in the oriens and in the radiatum 
strata. A less intense signal was detected in the stratum lacunosum molecolare (Fig. 18 C). 
The expression pattern profile observed in the Op hippocampus is similar to that in Syrian 
Hamster [186]. 
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Figure 16. PrPC expression in histoblots of P15 and P20 Op brains. (A-B) In coronal 
sections of P15 and P20 Op brains, a PrPC signal was detected in the thalamus (Th), in the 
neocortex (NCx) and in the hippocampus (H). The pyramidal layer (pyr) and the granule 
cell layer (gr) of the hippocampus were not stained by PrPC. (Bars: A-B 4 mm). 
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Figure 17. PrPC expression in P37 Op coronal brain sections. (A-B) Coronal sections in 
the caudal diencephalon from P37 Op were stained for PrPC in the thalamus (Th) and in the 
parenchyma of the hippocampus. In the ventral thalamus, a strong IR was observed in the 
reticular nucleus (Rt) and in the nucleus reuniens (Re). No IR was detected in the optic 
tract (Ot). In the hypothalamus (H) the IR was lower than in the Th. (B) A strong PrPC 
signal was observed in the stratum oriens (or) and in the radiatum (rad) of the 
hippocampus. A low PrPC signal was found in the hilar region (h) of the hippocampus, 
while the pyramidal (pyr) and the granule (gr) cell layers of the CA1-CA3 and of the DG 
were devoid of immunostaining. (Bars: 1 mm). 
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Figure 18. Coronal section of adult Op (P70) (A-C). In (A) the coronal section was 
Nissl-stained. In adult Op (B) a strong signal was predominantly present in the 
hippocampus. Marginal signal was also detected in the caudate nucleus (C), in the internal 
capsule (iC) and in the Putamen (Pu). A very residual signal was observed in the external 
capsule (eC). In (C) the specific distribution of PrPC in the different hippocampal layers 
was analyzed. Staining in the lacunosum and moleculare (lac/mol) was lower than in the 
oriens (Or) and in the radiatum (Rad). PrPC IR was also observed in the subiculum (Sb) the 
main output of the hippocampus. (Bars: 0.5 mm). 
 
3.5. PrPC expression in mouse brain coronal sections detected by histoblot 
Histoblots of P30 PrP WT (PrP+/+) mouse brain coronal sections were immunostained to 
measure differences in PrPC localization between Op and Mo (Fig. 19 A-B). The lack of 
signal in P30 PrP knock-out (PrP-/-) coronal sections (Fig. 19 C-D) confirmed the 
specificity of the D18 antibody signal. Ponceau staining was performed to ensure the 
presence of the brain section on the nitrocellulose membrane. The pattern of PrPC 
distribution in P30 PrP+/+ Mo was detected in many structures throughout the brain (Fig. 19 
A-B). At P30 strong IR was observed in the alveus, a thalamo-limbic structure of fornix 
fibers surrounding the stratum oriens that contains the axons of pyramidal neurons. As 
observed with the immunofluorescence staining, a well-defined PrPC signal was present in 
the stratum lacunosum-molecolare (Fig. 19 A). Strong labeling of the white matter fiber 
bundles was particularly evident at the level of the corpus callosum — the major 
interhemispheric fiber bundle in eutherians — and in the anterior commissure, also 
involved in interhemispheric communication [187]. Within the limbic system, a signal was 
also detected in the hippocampal fimbria, in its continuation, the fornix and in the 
! '(!
hippocampus. In the neocortex, staining was detected in a region adjacent to the ependymal 
layer. 
!
Figure 19. Histoblot of P30 PrP+/+ and PrP-/- mouse brain. (A) At P30 a well-defined 
PrPC signal was present in the hippocampal stratum lacunosum molecolare (lac/mo) and in 
the alveus (alv) lying just deep to the stratum oriens (or). (B) In the septum-caudatum, PrPC 
signal was detected predominantly in white matter fiber bundles, such as the anterior 
commissure (ac) and the corpus callosum (cc). The dark dots observed in the caudate-
putamen (CPu) are fiber fascicles cut on end. (C) At P30, the lack of staining in PrP-/- Mo 
coronal section confirmed the signal specificity. (D) The presence of the brain section on 
the nitrocellulose membrane was confirmed by Ponceau staining. (Bars: A-D 0.5 mm). 
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3.6 Efficiency of Op substrate in supporting the amplification of Op PrP PK-resistant 
from different prion sources 
Although prion diseases have not been reported in the Op so far, the differential expression 
profile might account for a different susceptibility to prions in general or to diverse prion 
strains in particular, as well as for a different pattern of PrPSc accumulation and propagation 
between placentals and marsupials. To gain more insights into this issue, serial automated 
PMCA (saPMCA) experiments were performed in collaboration with Prof. J. Castilla in 
Bilbao, using different scrapie inocula in adult Op brains. Normal Op brain homogenates 
were seeded in vitro with scrapie mouse adapted prion strains (RML, 22L), scrapie, chronic 
wasting disease (CWD), and bovine spongiform encephalopathy (BSE) adapted in sheep. 
Normal Op brain homogenates were then subjected to serial automated PMCA (saPMCA) 
in an attempt to assess their ability of generating Op PrPres. Seeded samples from round 10 
and the unseeded sample were digested with 100 µg/mL of proteinase K (PK) and analyzed 
by Western blot using the mouse polyclonal antibody 506A. This preliminary experiment 
indicated that the only inoculum able to cross the Op barrier is the BSE adapted in sheep 
(Fig. 20).  
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Figure 20. PMCA generation of PK-resistant OpPrP. (A-B) Using only normal Op 
brain homogenate as a substrate for PMCA, PrPC was efficiently converted to Op PK-
resistant PrP only when seeded with strains originating from BSE in sheep. (A)!Op brain 
homogenates seeded with different prion strains (mouse: RML, 22L, scrapie, mule deer: 
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CWD, cattle: BSE, sheep) or unseeded (de novo) were subjected to saPMCA. Seeded 
samples and the unseeded sample from round 10 were tested for proteinase K (PK) 
resistance and analyzed by Western blot. (B) Normal Op brains seeded with BSE adapted 
in sheep shows PK resistance at round 14 and 15 of PMCA. Normal brain homogenate was 
used as control. 
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3.7. PrPC and Reelin expression in the mouse hippocampus  
In different eutherian species, PrPC preferentially localizes in specific hippocampal layers. 
In the adult the strongest immunoreactive strata are the oriens and the radiatum, whereas in 
mouse PrPC specifically localizes in the stratum lacunosum-moleculare. 
In an attempt to explain the differences in PrPC distribution in the hippocampus of mouse 
and Op, we focused on proteins that are localized in this area and share similar functions to 
PrPC in the hippocampus. Among all the proteins that are expressed in this region our 
investigation focused on Reelin, a large extracellular matrix protein that plays an important 
role in regulating neural migration and synaptogenesis during development [188].  Reelin 
and Reelin mRNA have been detected in the stratum lacunosum molecolare [181] of 
mouse and Op hippocampi. To gain more insights in this issue we decided to analyze the 
effect of PrPC ablation in the Reelin signaling pathway using PrPC knock-out mice as no 
PrPC is expressed in their hippocampal layers. 
The distribution of Reelin was analyzed in the hippocampus of P3 mouse PrP WT and P4 
mouse PrP knock-out by immunohistochemistry (Fig. 21 and Fig. 22). In both genotypes, 
Reelin preferentially localizes in the stratum lacunosum molecolare, where PrPC IR is high 
in the PrP WT genotype.  
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Figure 21. PrPC and Reelin expression in the MoPrP+/+ hippocampus. 
Immuohistochemical staining for PrPC (red; C) and Reelin (green; B). A merged image is 
shown in (D). (A-D) At P3, PrPC and Reelin were detected in the stratum lacunosum 
molecolare (Str l m) of the hippocampus. (Bars: 210 *m). 
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Figure 22. Reelin expression in MoPrP KO hippocampus. (A) DAPI staining of mouse 
hippocampus in coronal section. (B, D) In the early postnatal PrP KO mouse hippocampus, 
Reelin IR was detected in the stratum lacunosum moleculare (Str l m). (C) No PrPC 
immunostaining was observed. (A-D Bars: 80 *m). 
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3.7.1 Reelin-signaling is enhanced in the hippocampus of early postnatal  
PrP-deficient mice 
PrPC is highly expressed in the developing brain and it is involved in physiological events 
in which the Reelin-signaling pathway plays a key role. Therefore, we tested whether PrP 
deficiency is accompanied by changes in levels of Reelin in the early postnatal brains of 
PrP knock-out versus WT. Western blot analysis with a Reelin N-terminus antibody 
showed several Reelin isoforms, with the most intense band migrating at ~460 kDa, ~140 
kDa and ~70 kDa (Fig. 21 A). Although the levels of full-length Reelin were unchanged 
between PrP WT mice and PrP KO mice, an increase in the isoforms at ~140 kDa and ~70 
kDa was found in PrP-deficient samples (*p<0.05, n+4, paired t test) (Fig. 23 A-B). 
Interestingly, when PrP is overexpressed (Fig. 23 C lanes 7 and 8), independent of the 
constructs, there seem to be less Reelin (in the 460 kDa and ~150 kDa bands). Lane 7 was 
loaded with a brain homogenate derived from PrP('STE) mice which are  constructed by 
deleting the stop transfer effector sequence (STE). Mice with this mutation overexpress 
PrPC and can generate almost uniquely the secretory PrPC (SecPrP) conformation [189]. 
Lane 8 was loaded with a brain homogenate of a PrP(KH>II) mouse. This transgenic 
mouse contains amino acid substitutions lysine and histidine to isoleucines at positions 110 
and 111, in the stop transfer effector sequence. It over-expresses PrPC and favour the 
CtmPrP conformation whith the COOH-terminus in the lumen and the NH2-terminus in the 
cytosol [189]. 
To analyze the involvement of PrPC in the Reelin-signaling pathway, we compared the 
levels of PrPC in Reelin-deficient mice (Reeler) and in Reelin WT mice (Reelin WT). 
Remarkably, levels of PrPC were increased in Reeler compared with Reelin WT mice (Fig. 
23 D), further supporting a possible relationship between Reelin and PrPC.  
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Figure 23. The expression of 140 kDa and 70 kDa Reelin isoforms increased in PrP-
deficient mice whereas PrPC expression increased in Reelin-deficiet mice. (A-B) PrP 
KO and PrP WT hippocampi were probed by Western blot with an antibody against the 
Reelin N-terminus. Note increased levels of the ~140 kDa and of the ~70 kDa forms of 
Reelin in PrP KO versus PrP WT samples. ß-actin was used as loading control. (B) The 
graph shows the quantification of the blots (mean±SEM, n+4). The levels of each Reelin 
isoform were normalized to ß-actin. *p<0.05, paired t test. (C) To confirm that the 
expression of Reelin fragments was increased in absence of  PrPC we probed different brain 
samples from PrP WT and PrP KO mice with a different genetic background with an 
antibody against the Reelin N-terminus and against PrPC. ß-actin was used as loading 
control. Samples were loaded as follows: (1) FVB PrP KO; (2) FVB PrP WT; (3) FVB PrP 
WT; (4) FVB PrP KO; (5) C57/B6; (6) SvEv 129 PrP WT; (7) PrP('STE); (8) PrP 
(KH>II); (9) Ola129.  Lines (1-4) were loaded with FVB mice from different animal 
houses to confirm that our results were not due to the genetic background of the Prnp0/0 
strain maintained by inbreeding.  (D) Reeler and Reelin WT brain samples were probed by 
Western blot with antibodies against PrP. ß-actin served as loading control. 
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Since PrP knock-out mice have no overt phenotype [190], we set out to test whether an 
impairment in the expression of downstream components of the Reelin-signaling pathway 
may mask the phenotype of PrPC deficient mice or may it help to explain some subtle 
differences described in the literature. 
Reelin signals by binding to two transmembrane receptors, apolipoprotein E receptor 2 
(ApoER2) and very-low-density lipoprotein receptor (VLDLR) [189]. To a certain extent, 
both receptors can compensate for each other, and only the loss of both receptors results in 
the Reelin ko phenotype, which is characterized by gross defects in the architecture of the 
laminated structures [191], such as the cerebellum, the cortex and the hippocampus. 
Although both VLDLR and ApoER2 are members of the low-density lipoprotein family, 
they differ in a number of ways, including structural differences, expression patterns, 
alternative splicing, and binding of extracellular and intracellular proteins. Subcellularly, 
VLDLR is present in non-lipid raft fractions, whereas ApoER2 is found in lipid raft 
fractions of cell membranes [191]. We therefore analyzed the different expressions of both 
Reelin receptors in the hippocampus of PrP knock-out and PrP WT mice. The overall 
expression of both receptors does not differ between the two genotypes (Fig. 24 A-B). 
Because PrP and ApoER2 are both localized in the lipid raft compartments, we wondered 
whether they may form a complex. Hence, we immunoprecipitated ApoER2 from 
hippocampus homogenates and analyzed immunoprecipitates with an antibody against PrP. 
PrP coimmunoprecipitated with ApoER2 (Fig. 24 C), thus indicating that the two proteins 
are associated in the hippocampus. Both VLDLR and ApoER2 have short cytoplasmatic 
tails that contain an NPxY motif to bind Dab1 (Disabled binding protein 1), an intracellular 
adapter protein expressed in cells that respond to the Reelin signal. Dab1 contains five Tyr 
residues and phosphorylation of these residues, in response to the binding of Reelin to 
lipoprotein receptors, is necessary for Dab1 function [192]. It has been shown that Dab1 is 
a target for the fibrillar PrP (106-126) or PrPres-induced oxidative stress both in vitro and in 
inoculated hamsters [193]. We therefore measured the levels of total Dab1 and Tyr-
phosphorylated Dab1 (pDab1) in the hippocampus of early postnatal PrP KO and PrP WT 
mice (Fig.25 A-D). We immunoprecipitated lysates with anti-Dab1 and anti total phospo-
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tyrosine antibodies and we probed for Dab1. We found that Tyr-phosphorylated Dab1was 
increased in PrP KO mice (*p<0.05, n=3, paired t test) (Fig. 25 C-D), despite total Dab1 
was expressed to a similar degree in both genotypes (Fig. 25 A-B). 
 
Figure 24. ApoER2 and VLDLR expression in the hippocampi of PrP KO and PrP 
WT mice. (A-B) Hippocampus homogenates of P1 PrP KO and PrP WT mice were 
immunoblotted with antibodies against ApoER2 or VLDLR. Diagrams show quantitation 
of both receptors normalized against ß-actin. Note that the amount of both receptors is 
similar in the hippocampi of  both genotypes. (C) ApoER2 immunoprecipitates from PrP+/+ 
and PrP-/- hippocampi were immnunoblotted with PrP antibody. IgG served as control. 
Hippocampus homogenates (inputs) were also probed for ApoER2 and PrP. 
! ((!
 
Figure 25. PrP-/- mice have an increased level of pDab1 but not total Dab1. (A,C) 
Hippocampus homogenates from PrP knock-out and PrP WT mice were blotted for total 
Dab1. The histogram represents the quantitative results of total Dab1 in both genotypes 
normalized against ß-actin (mean±SEM, n=3). (B, D) PrP knock-out mice have increased 
pTyr Dab1 compared to WT mice. The graph in (D) shows the ratio of tyrosine 
phosphorylated Dab1 normalized to total immunoprecipitated Dab (mean±SEM, n=3). 
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Phosphorylated Dab1 subsequently interacts with other proteins including lissencephaly 
protein 1 [151] and phosphatidylinositol 3-kinase (PI3K) [152]. Activation of PI3K leads to 
further downstream signaling including activation of Akt and alterations in glycogen 
synthase kinase 3% (GSK3%) and tau [153]. GSK-3 activity is increased by phosphorylation 
of a tyrosine residue, Tyr-216 in GSK-3% and Tyr-279 in GSK-3", located in the kinase 
domain. This phosphotyrosine is important because its dephosphorylation diminishes 
activity [194] [195]. Phosphorylated DAB1 inhibits GSK3%, a kinase known to 
phosphorylate Tau protein at multiple sites. The analysis of the gene expression profile in 
the hippocampi of early postnatal PrP knock-out and WT mice showed that in absence of 
the Prnp gene, the expression of GSK3% was downregulated [196]. Furthermore, it has 
been reported that in cultured neurons the addition of the prion peptide (PrP 106-126) 
increases the activity of GSK3 and is accompanied by the enhanced phosphorylation of 
some microtubule-associated proteins, including tau and microtubule-associated protein 2 
[197]. We next investigated whether the levels of total GSK3% and phosphorylated GSK3% 
were affected in the early postnatal hippocampi of our animal models (Fig. 26). 
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Figure 26. PrP WT mice have higher levels of GSK3! phosphorylated on Tyr216 than 
PrP KO mice. (A) Total hippocampus homogenates were prepared from 3 P1 PrP WT  
mice and 4 PrP knock-out mice as described above. Thirty micrograms of protein were 
loaded in each lane and immunoblotted for indicated proteins. (B) Quantification data 
obtained from the densitometric analysis of total GSK3%, GSK3% phosphorylated on Tyr 
216 (51 kDa) and %-actin. 
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In agreement with an increased activation of Dab1 in PrP knock-out mice, we found that 
the ratio between GSK3% phosphorylated on Tyr 216 and total GSK3% normalized on %-
actin was significantly higher in newborn mice expressing PrPC compared with the knock-
out counterparts (*p<0.05, n+3, paired t test). 
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Chapter Four 
!
DISCUSSION 
!
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Over the last twenty years, the pattern of PrPC expression profile in the CNS of placental 
mammals such as mouse (Mo) and Syrian Hamster (SHa) has been extensively 
investigated. In this work we described a detailed analysis of PrPC expression in the 
developmental mouse CNS, both at protein and at mRNA level. To check whether this 
expression pattern was maintained in other species, we focused our analysis on the 
metatherian South American short-tailed opossum (Monodelphis domestica) (Op). The 
most striking difference observed between the two species was the different localization of 
PrPC in the white matter. The lower PrPC signal in Op white matter structures argues for a 
lower expression of the protein by glial cells and neuronal axons. Athough prion diseases 
have not been reported in the Op so far, the differential expression profile might account 
for a different susceptibility to prions in general or to diverse prion strains in particular, as 
well as for a different pattern of PrPSc accumulation and propagation between placentals 
and marsupials. We also found that in different mammals PrPC localizes in different 
hippocampal layers. In the mouse, PrPC is preferentially localized in the synapse-rich 
stratum lacunosum molecolare, whereas in the Op the strongest immunoreactive layers are 
the oriens and the radiatum. This finding suggested that PrPC might play a different 
regulatory role in the synaptic activity of different mammals. This function might be 
mediated by other proteins that are localized in the same hippocampal layer and share 
functions similar to that of PrPC in the hippocampus. In particular we decided to focus our 
analysis on the Reelin-signaling pathway, which plays a pivotal role in synaptogenesis 
during development [198]. 
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4.1. PrPC and Prnp  expression in the developmental mouse brain 
By in situ hybridization we identified PrPC mRNA expression in two layered brain 
structures, the cortex (Fig. 12) and the hippocampus (Fig. 13). In the former, we described 
Prnp gene expression at E14.5 in the VZ, a proliferative brain area underneath the MZ 
where the newborn neurons are. The MZ is the outermost layer of the cerebral cortex. MZ 
cells are known to orchestrate the development of the cortical layers and contribute to the 
GABAergic interneurons in the cerebral cortex [199]. At P1 Prnp was detected in the 
SVZ/E layer of the neocortex, in which the neurogenesis persists throughout the animal’s 
adult life, suggesting a possible involvement of PrPC in the cellular proliferation control 
along development [87]. However, when the proliferative rate of cells is very high (at 
E14.5) PrPC is not expressed in the BrdUrd positive cells, hence suggesting that PrPC might 
not be directly involved in cell proliferation (Fig. 12 G). 
In the developmental neocortex the mRNA expression of PrPC seemed to parallel the time 
course of neuronal cellular differentiation, since at P1 we described a Prnp signal through 
the cortical layers 6-2, while at P7 the signal still spanned all the neocortex but was higher 
in the uppermost than in the inner layers (Fig. 12). 
During early postnatal brain development we found a strong PrPC signals in the 
hippocampus, both at protein (Fig. 10) and at mRNA levels (Fig.13). Since in this layered 
structure the strongest IR was observed in the stratum lacunosum molecolare — a synapse-
rich region where hippocampal interneurons [200] and afferent neuronal inputs [201] make 
connections — we might argue an involvement of PrPC in synapse development and 
activity. Indeed the lack of PrPC has been related to a hippocampal synapatic impairment 
[76]. Central synapses have also been described as primary dysfunctional victims in prion 
diseases, before neurodegeneration occurs [202,203]. The strong developmental regulation 
and expression of PrPC in the hippocampus and in the neocortex is intriguing, as it may 
account for the increased susceptibility of Prnp mice to epileptic seizures [118]. The lack 
of PrPC may alter the physiological development of these brain structures, and in turn 
provoke changes in interneuronal connections and neural network properties. 
In all the developmental stages analyzed we described a strong PrPC signal in brain fiber 
bundles participating in the regulation of the thalamolimbic circuitry, such as the 
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fimbria/fornix, the stria terminalis and the fasciculus restroflexus (Fig. 10 and Fig. 11). 
This might reflect an active axonal transport of the PrP through these structures. In 
particular, PrPC expression in the fimbria/fornix could be related to an axonal transport 
from the hippocampus PrPC [72]. 
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4.2. Mapping the PrP distribution in marsupials: Insights from comparing Op with 
mouse CNS 
To date, little is known about PrPC distribution in marsupial mammals for which no 
naturally occurring prion diseases have been reported. To extend our understanding of 
varying PrPC expression profiles in different mammals we carried out a detailed expression 
analysis of PrPC distribution along the neurodevelopment of the metatherian South 
American short-tailed Op (Monodelphis domestica). 
 
4.2.1. Technical remarks about PrPC detection in Op brain 
The routine histological techniques might not be sensitive enough to map PrPC expression 
in the Op brain. We tested different immunofluorescence protocols in combination with 
several monoclonal antibodies (Tsble 1), but none of them appeared to work (Fig. 15). We 
speculated that these technical difficulties experienced with the traditional 
immunohistochemical staining techniques might be due to a weak antibody affinity for Op 
PrP (OpPrP), possibly ascribable to epitope masking as a result of a different membrane 
environment. Alternatively, PrPC signal might be masked by another molecule, which 
could make the binding of the antibody to the antigene inaccessible. To overcome these 
difficulties we decided to use the immunohistoblot technique described by Taraboulos et al. 
[182] to map the regional distribution of PrPSc in the brain of diseased SHa. The use of 
0.1M sodium hydroxide enhanced the binding of PrP antibodies [204] thus allowing for the 
detection of a clear PrPC signal in the cryostat sections of the freshly frozen Op brain 
tissues in this study. 
 
4.2.2. Comparison of PrPC distribution between marsupials and placental mammals 
Our results showed that from the day of birth (P1) up to adulthood (P75) PrPC was 
detectable by Western blotting in whole brain homogenates (Fig. 14 B) with the strongest 
PrPC signal in the uppermost diglycosylated band (~37 kDa) and the weakest signal in the 
lowest non-glycosylated PrPC band (~26 kDa). A change in PrPC relative abundance was 
observed during Op brain development, corroborating previous evidence of a 
developmentally regulated expression of PrPC. In the different brain regions under 
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consideration, PrPC levels either remained at plateau or decreased slightly in adulthood 
(Fig. 14 C). Interestingly, after the time of weaning a tendency to an increase in PrP 
expression was observed in the olfactory bulbs. As postulated for placental mammals [186] 
this finding might be related to ongoing plasticity of the olfactory bulbs also in marsupials. 
However, no evidence is available yet to suggest that there is indeed plasticity in the 
olfactory bulbs of adult marsupials. 
At P37 we observed a strong PrPC immunoreactivity in the thalamus, a region which has a 
strong nonphotic influence on sleep and circadian rhythmicity [205]. This finding 
suggested an evolutionary conserved involvement of PrPC in sleep homeostasis in the Op, 
in which a functioning circadian timing system exists [206-208]. 
Before weaning, PrPC was detectable in the parenchyma of the hippocampus (Fig. 15 B). 
Interestingly, in different eutherian species, PrPC preferentially localizes in specific 
hippocampal layers. In the adult Op (Figure 18C) and SHa [186] the strongest 
immunoreactive strata are the oriens and the radiatum, whereas MoPrPC specifically 
localizes in the stratum lacunosum moleculare (Fig. 19 A). These results seem to suggest a 
different regulatory role of PrPC in the synaptic activity of different species. The lack of 
PrPC in the nerve cell bodies was implied by the absence of signal in the pyramidal-cell 
layer and granule cell-layer of the dentate gyrus in both Mo and Op.  
The most striking difference observed between the two species was the different 
localization of PrPC in the white matter. The lower PrPC signal in Op white matter 
structures argues for a lower expression of the protein by glial cells and neuronal axons. In 
P30 mice instead, a strong PrPC immunoreactive signal was detectable in the corpus 
callosum, a specific eutherian structure enriched in myelinated axons and involved in 
interhemispheric communication [209]. 
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4.2.3. Implications for TSE pathology 
The different ability of prions to infect (or not infect) certain species is apparently encoded 
by their structural features, which result in different physio-pathological outcomes [210]. 
This strain-like behavior is known as the prion transmission barrier. However, under 
controlled laboratory conditions, prions are able to adapt and infect species previously 
believed to be TSE resistant, as was recently reported in rabbits infected by the murine 
ME7 prion strain using protein misfolding cyclic amplification (PMCA) [211]. Telling and 
his coworkers have recently developed a Tg mice line [Tg(EqPrP)SS251] expressing the 
equine PrP to study the susceptibility to TSEs in putatively resistant animals [212]. Their 
preliminary results suggest that these mice are resistant to all common prion strains, 
reinforcing the idea that prion resistance seems to be enciphered by PrPC sequence. 
Structural studies on the recPrP of mammals for which no TSEs have been reported in 
natural conditions [e.g. horse, rabbit and the marsupial Tammar wallaby (Macropus 
eugenii)], postulated that resistance to prions might be due to some structural features in the 
globular domain of those mammalian PrP sequences [30,31,213]. The OpPrP sequence 
presents an outstandingly large number of amino acid substitutions at the N-terminal in the 
copper binding sites and, within the C-terminal domain, in epitopes (residues 163-174 and 
221-230 in Mo numbering, Fig. 27) critical for prion conversion [8,33,36,37,214]. 
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Figure 27. Comparison of amino acid sequences and secondary full-length PrP 
structure of selected mammalian species: mouse (MoPrP; Mus musculus, GenBank 
accession number: AAA39997), human (HuPrP; Homo sapiens, AAA60182), Syrian 
hamster (ShPrP; Mesocricetus auratus, AAA37091), sheep (OvPrP; Ovis aries, 
ABC61639), elk (ElPrP; Cervus elaphus nelsoni, AAB94788), bank vole (BvPrP; 
Clethrionomys glareolus, AAL57231), horse (EcPrP; Equus caballus, ABL86003), rabbit 
(RaPrP; Oryctolagus cuniculus, AAD01554), tammar wallaby (TwPrP; Macropus eugenii, 
AAT68002) and opossum (OpPrP;!Monodelphis domestica, CBY05848). 
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Based on this sequence identity analysis, it is possible to argue that these amino acidic 
differences might have an impact on the ability of OpPrP to sustain prion conversion. On 
the other hand, if structural differences in mammalian PrP are important for understanding 
the molecular mechanisms of TSEs, the neuronal distribution of PrPC in mammalian 
species that are putatively resistant to prion diseases should be considered.  
It is noteworthy that PrPSc accumulates in the white matter areas of mouse and Syrian 
hamster brains, thus suggesting that glial cells may be the primary targets for prions 
[182,215]. Indeed, the infectious agent has been shown to spread from the needle track 
along white matter pathways towards the gray matter [216]. This hypothesis is strengthened 
by pathological studies in human brains of terminal CJD patients showing axonal damage, 
hence suggesting a transport of prions through white matter pathways [217]. 
Although prion diseases have not been reported in the Op so far, the differential expression 
profile might account for a different susceptibility to prions in general or to diverse prion 
strains in particular, as well as for a different pattern of PrPSc accumulation and propagation 
between placentals and marsupials. To gain more insights into this issue, serial automated 
PMCA (saPMCA) experiments were performed in collaboration with Prof. J. Castilla in 
Bilbao, using different scrapie inocula in adult Op brains.! This preliminary experiment 
indicated that the only inoculum able to cross the Op barrier is the BSE adapted in sheep 
(Fig. 20). This result corroborates the idea that BSE in sheep is one of the most 
promiscuous and infectious inocula described to date [218]. It also seems to suggest 
putative difficulties in overcoming the species transmission barriers in infectivity in vivo 
experiments with the regular inocula.  
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4.3. Increased activation of the Reelin-signaling pathway in early postnatal mouse 
hippocampus lacking PrPC 
Our findings show that the hippocampus is one of the brain regions with the earliest 
expression of PrPC along neural development. Interestingly, we showed that PrPC has a 
specific localization in this layered structure among mammals. In the mouse it is mainly 
expressed in the stratum lacunosum molecolare, whereas in the Op it is located in the 
adjacent layers. Based on the overall pattern of findings discussed here, we hypothesized a 
connection between PrPC and another protein specifically expressed in the stratum 
lacunosum molecolare, and this connection may be dysregulated in absence of PrPC. To 
investigate this hypothesis, we examined the possible candidates to ascertain whether they 
share the same physiological functions as PrPC in the hippocampus. Among all the putative 
candidates we decided to focus our attention on the extracellular matrix protein Reelin, as 
Schachner and coworkers [114] have shown a functional interaction of Reelin with PrPC in 
the developing mouse brain. Reelin was expressed in the stratum lacunosum moleculare in 
the mouse hippocampus (Fig. 21-22) and its mRNA was detected in the same location also 
in the Op [181]. The lack of PrPC knock-out Op did not allow us to make further 
speculations about the physiological role of PrPC in the hippocampus of this animal model. 
To overcome these difficulties we targeted our analysis on the brains of PrPC knock-out 
mice in which no PrPC is expressed in the different hippocampal layers. 
Reelin is a glycoprotein of the extracellular matrix involved in different neuronal cellular 
functions. In particular, it has been shown to regulate neural migration and synaptogenesis 
during development [219], it is a key component of synaptic plasticity [220] in adult brain, 
it increases NMDA receptors subunit activity [221] as well as the number of 
transmembrane proteins in synaptosomal membranes [161] and it influences neuronal 
cellular function via interactions with cell-surface receptors such as integrins [222]. The 
involvement in the proper homeostatic functioning of hippocampal circuits [223], the 
association with integrins [224] and the modulation of synaptic NMDA activity are also 
features associated with PrPC [119]. In vivo, PrPC and Reelin demonstrate similar regulation 
throughout brain development, with both peaking early in post-natal development. To gain 
more insights into a possible interaction between PrPC and Reelin we tested whether the 
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absence of PrPC may cause impairments in the signaling pathway triggered by Reelin in the 
early postnatal mice hippocampus. 
Reelin is a huge secretory serine protease, which appears in Western blot as several protein 
bands, ranging from 410 to 330 kDa. In the extracellular and/or post-endoplasmic 
environment it appears as subjected to proteolytic cleavage at two sites, which generate 
smaller fragments [225]. Differently from what had been previously reported [114] we did 
not find a significant difference in the expression levels of the full length Reelin between 
PrPC WT and knock-out mice (Fig. 23 A-B). Interestingly, in the brains of PrP('STE) mice 
overexpressing and favoring the secretory-GPI-anchored SecPrP expression [226] and in 
PrP(KH>II) mice, overexpressing and favoring the C-transmembrane form of PrP (CTMPrP) 
[227] there seemed to be less Reelin in the 460 kDa bands (Fig. 23 C). Using antibodies 
raised against the Reelin N-terminal we found that the expression of the isoforms at 140 
kDa and 70 kDa increased in the hippocampus of PrP-deficient mice (Fig. 23 A-B). A 
higher expression of the truncated forms of Reelin concomitant with a decrease of PrPC 
expression was also found in different constructs. This suggests that our findings do not 
depend on the mice genetic background (Fig. 23 C) and that the absence of PrPC might be 
associated with an increased processing of Reelin, mediated by a metalloproteinase, 
probably belonging to the adamalysins and astacins [135]. Adamalysin and astacin activity 
or expression might be differently modulated by the presence PrPC. The proteolytic 
processing of Reelin has been reported to be important from a functional point of view, and 
the full activity of Reelin might require degradation of the full-length precursor to generate 
smaller, more active isoforms [129]. There is controversy over which cleavage product 
activates the Reelin signal transduction cascade on target cells. In some studies, the so-
called central Reelin fragment, consisting of repeats 3– 6, has been proved crucial for 
receptor activation [131], whereas others claim that a smaller fragment, repeats 5– 6, is also 
important [228].  
These observations, together with the higher PrPC expression in the brain of Reeler mice 
than in their WT counterparts (Fig. 23 D), seem to reinforce the hypothesis of a 
compensatory expression for these two proteins. 
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The effects of Reelin are mediated by the concomitant binding of a pair of homologous cell 
surface receptors designated as apolipoprotein E receptor 2 (ApoER2) and very low-density 
lipoprotein receptor (VLDLR). We did not observe any significant difference in the 
expression levels of either receptor in the early postnatal hippocampi of PrPC WT and PrPC 
knock-out brains (Fig. 24 A-B). Differently from VLDLR, ApoER2 and PrPC are mainly 
associated with lipid rafts. The possibility that they may form a complex is supported by 
coimmunoprecipitation experiments (Fig. 24 C). The existence of a functional interaction 
of PrPC and lipoprotein receptors is also supported by the ability of the recPrP to form 
complexes with both recombinant and native ApoE [229]. 
Reelin-signaling is relayed by the Dab1 adaptor protein, interacting with the cytoplasmic 
tail of receptors and it is phosphorylated by Fyn and Src tyrosine kinases (SFK) [148]. Our 
observation that in the hippocampus of PrP knock-out mice the levels of activated Dab1 are 
higher than in PrPC WT mice is controversial. On the one hand, the activation of the fyn 
kinase seems to be reduced in PrP knock-out mice [89] but on the other, partial Reelin 
fragments, whose levels are enhanced in absence of PrPC, have been shown to be efficient 
in Dab1 phosphorylation assay [131]. The observation that in primary neuronal cell 
cultures the increased intracellular ROS generation and oxidative stress induced by 
treatment with the fibrillar PrP fragment PrP (106–126) is responsible for Dab1 
phosphorylation [193] seems to be consistent with our results and with the increased 
susceptibility to neuronal damage by oxidative stress in absence of PrPC [65]. 
Activated Dab1 suppresses the activities of glycogen synthase kinase-3% (GSK-3%), a 
kinase known to phosphorylate tau at multiple sites, including some of those found in 
neurofibrillary tangles (NFTs) [230]. Specific biochemical assays of brain lysates have 
shown that the activity of GSK-3% increased significantly in Reeler mice and that it was 
considerably higher in mice lacking both Reln and ApoE. Thus, the observation that the 
expression of Reelin products seems to be different in absence of PrPC, led us to 
hypothesize a different activation of GSK-3%. Microarray analyses using RNA isolated 
from the hippocampus of newborn PrPC WT and PrPC knock-out mice have shown that the 
GSK-3% gene was downregulated in Prnp0/0 mice [196]. Interestingly we observed that in 
PrPC WT mice the levels of activated GSK-3% normalized on total Gsk3% were higher than 
in PrPC knock-out mice (Fig. 26 A-B). This seems to agree with an higher phosphorylation 
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of Dab1, probably due to an increased activation of the two lipoprotein receptors by partial 
Reelin fragments in absence of PrPC. Unlike other protein kinases, GSK-3 is constitutively 
active under resting conditions and is inactivated by extracellular signals through 
phosphorylation of an N-terminal serine residue, Ser-9 in GSK-3% and Ser-21 in GSK-3". 
Various kinases have been implicated in mediating serine phosphorylation and inactivation 
of GSK-3, including PI3-kinase (PI3K)-regulated Akt/PKB, protein kinase A and protein 
kinase C (PKC) [231] [232]. We might hypothesize that the elevated PI3K activity in brain 
lysates from WT mice, as compared to PrP knock-out mice [102] results in a major 
phosphorylation of Ser21 on GSK-3" and Ser9 on GSK-3%.  The latter inhibits GSK-3 
activity and in turn might explain the higher phosphorylation levels of tau observed during 
early postnatal development in absence of PrPC [196]. 
 
In this work we explored a possible involvement of PrPC in the Reelin-signaling pathway in 
the early postnatal mouse hippocampus. Both proteins share some common features in the 
context of their physiological role in the hippocampus. Our observations suggest an 
interesting scenario in which the absence of PrPC may provoke impairment in the 
downstream signaling events promoted by Reelin. Our findings lead us to hypothesize a 
functional crosstalk between PrPC and the Reelin-signaling complex. This may contribute 
to explain the phenotype described in the hippocampus of PrPC knock-out mice, namely the 
enhanced neuronal excitability that might be linked to a role for Reelin in the regulation of 
the NMDA receptor. 
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ABSTRACT
Transmissible spongiform encephalopathies (TSEs) are
neurodegenerative disorders caused by PrPSc, or prion,
an abnormally folded form of the cellular prion protein
(PrPC). The abundant expression of PrPC in the central
nervous system (CNS) is a requirement for prion repli-
cation, yet despite years of intensive research the phys-
iological function of PrPC still remains unclear. Several
routes of investigation point out a potential role for
PrPC in axon growth and neuronal development. Thus,
we undertook a detailed analysis of the spatial and
temporal expression of PrPC during mouse CNS devel-
opment. Our findings show regional differences of the
expression of PrP, with some specific white matter
structures showing the earliest and highest expression
of PrPC. Indeed, all these regions are part of the thala-
molimbic neurocircuitry, suggesting a potential role of
PrPC in the development and functioning of this specific
brain system. J. Comp. Neurol. 518:1879–1891, 2010.
VC 2010 Wiley-Liss, Inc.
INDEXING TERMS: cellular prion protein; PrPC; Prnp gene; infectious isoform of PrP; PrPSc; neurodevelopment; limbic
system; hippocampal fimbria; fornix; stria terminalis; fasciculus retroflexus; stratum lacunosum
moleculare; neural circuit
Prions are the proteinaceous infective particles causa-
tive of transmissible spongiform encephalopathies (TSEs)
or prion diseases, fatal neurodegenerative disorders
including Creutzfeldt–Jakob disease (CJD), fatal familial
insomnia (FFI), and kuru in humans; bovine spongiform
encephalopathy (BSE) and scrapie in cows and sheep,
respectively; and the recently emerging chronic wasting
disease (CWD) in deer. According to the protein-only hy-
pothesis (Prusiner, 1982), prions are composed exclu-
sively of PrPSc, an abnormally folded form of the cellular
prion protein (PrPC). PrPC is a ubiquitous sialoglycoprotein
mainly expressed in the brain, particularly in neurons, and
anchored at the cell membrane surface with a glycosyl-
phosphatidylinositol (GPI) moiety.
Despite the striking evidence of an association of PrPC
pathological conversion with the etiology of prion dis-
eases, its physiological function is at present unknown.
Several putative functions of PrPC have been postulated,
including synaptic activity (Herms et al., 1999), mainte-
nance of myelinated sheet (Radovanovic et al., 2005),
neuroprotective functions (Bounhar et al., 2001), and
neurogenesis and differentiation (Steele et al., 2006).
Moreover, PrPC is able to stimulate neuritogenesis, rapid
polarization, and development of synapses in cultured
neurons (Kanaani et al., 2005; Santuccione et al., 2005).
All these features hint at PrP acting as a growth factor,
possibly involved in central nervous system (CNS) devel-
opment. Indeed, PrP expression was shown to be devel-
opmentally regulated (Mobley et al., 1988; Lazarini et al.,
1991; Manson et al., 1992; Sales et al., 2002; Tremblay
et al., 2007).
Here, by combining in situ hybridization and immuno-
histochemical techniques, we analyzed the spatiotempo-
ral expression of PrPC during mouse CNS development.
For this purpose we took advantage of the PrP-specific
monovalent recombinant antibody antigen-binding frag-
ment (Fab) D18 (Peretz et al., 2001). Our findings reveal
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regional differences in the expression of PrPC, with the
earliest expression of the protein in the hippocampus,
thalamic, and hypothalamic regions. In particular, specific
white matter fiber tracts (i.e., the hippocampal fimbria,
the stria terminalis, and the fasciculus retroflexus) show
the highest expression of the mature protein. All these
white matter fibers are part of the thalamolimbic system,
an integrated brain neurocircuitry that regulates circa-
dian, autonomic, and hormonal functions, as well as
stress response behaviors. Thus, the high neurodevelop-
mental expression of PrPC in these specific brain struc-
tures suggests a potential implication for PrPC in the cor-
rect development and functioning of the thalamolimbic
system. The localization of PrPC in nonneuronal cell types
will also be discussed.
MATERIALS AND METHODS
Animals
All experiments were carried out in accordance with
European regulations (European Community Council
Directive, November 24, 1986 (86/609/EEC)) and were
approved by the local veterinary service authority. C57/
B6 wildtype, B6/129 Prnp!/! (Bueler et al., 1992), FVB
wildtype, and FVB Prnp!/! (Lledo et al., 1996) mice were
used in these experiments. Embryonic and newborn ani-
mals were sacrificed and brains immediately collected
and washed several times in cold phosphate-buffered sa-
line (PBS) 1" pH 7.4 glucose 0.6% w/v. Then brains were
fixed by complete immersion in freshly prepared PBS 1"
paraformaldehyde (PFA) 4% with very gentle shaking over-
night at 4#C. The day after, the samples were washed in
PBS 1" and cryopreserved by complete immersion in
PBS 1" sucrose 30% with gentle shaking overnight at
4#C. Then brains were washed several times in PBS 1" to
remove excess glucose, included in OCT, and stored at
!80#C. Two-week-old and older animals were deeply
anesthetized, then perfused with PBS 1" and PBS 1"
PFA 4%. After perfusion, animals were decapitated and
brains were collected, fixed, and cryopreserved as previ-
ously described.
Immunohistochemistry
Ten-micrometer-thick brain serial sections were cut
with a cryostat and mounted onto Superfrost Plus coated
slides (Menzel-Gla¨ser, Madison, WI). Slides were thawed
at room temperature (RT), then washed with Tris-buffered
saline (TBS) þ Triton X-100 0.3% (TBSþT). Sections then
were blocked with blocking solution: TBSþT þ normal
goat serum (NGS) 10% and bovine serum albumin (BSA)
5% for 1 hour at RT. Slides were then incubated with pri-
mary antibodies diluted in blocking solution for 2 hours at
RT with gentle shaking. After washing the appropriate
secondary antibodies, diluted in blocking solution, were
added for 1 hour at RT with gentle shaking. Slides then
were extensively washed with TBSþT, mounted with Vec-
tashield (Vector Laboratories, Burlingame, CA), and ana-
lyzed under Leica fluorescence microscope. All data are
representative of at least three independent experiments.
Staining was performed on both FVB and C57/B6 genetic
backgrounds. As control, age-matched FVB Prnp!/! and
B6/129 Prnp!/! mice were used. The same exposure
times were used for acquisition of images from both wild-
type and Prnp knockout brain slices. Images were not
modified other than to balance brightness and contrast
with GIMP software, v. 2.6.7.
Antibodies
Recombinant anti-PrPC humanized (HuM) Fab D18 was
purchased from InPro Biotechnology (South San Fran-
cisco, CA; ABR-0D18) and used to a final concentration of
1 lg/mL. HuM-D18 is a recombinant Fab with human
constant moiety, first raised by immunizing Prnp!/! mice
against the protease-resistant core of Syrian hamster
(SHa) PrPSc (Peretz et al., 1997). It showed high affinity
for the region spanning the residues 133–152 incorpo-
rated in the first alpha-helix of PrPC (Williamson et al.,
1998), and proved to have a large accessibility to its spe-
cific epitope and to bind the largest fraction of the cell-
surface PrPC population, as revealed by cross-competi-
tion experiments (Leclerc et al., 2003). Moreover, it was
able to inhibit prion propagation and clear cell cultures of
prion infectivity (Peretz et al., 2001).
Anti-neurofilament 200 antibody was purchased from
Sigma (St. Louis, MO; N-4142) and used at dilution
1:800. This antibody is developed in rabbit using purified
neurofilament 200 from bovine spinal cord as the immu-
nogen. It localizes only the 200-kDa neurofilament poly-
peptide in immunoblotting from mouse brain
homogenate.
In situ hybridization
Twenty-lm-thick cryosections were cut and collected
on slides (Menzel Gla¨ser SuperFrost Plus) and then stored
at !80#C. Sections were dried at RT for 2 hours and fixed
in 4% PFA in PBS 1" at room temperature for 10 minutes,
washed in PBS 1", treated with 18 mg/mL Proteinase K
(Roche, Nutley, NJ) at 30#C for 15 minutes, washed in gly-
cine 4 mg/mL, PBS 1", and fixed once more in 4% PFA
for 10 minutes, washed, incubated in 0.1 M thriethanol-
amine pH 8.0 with acetic anhydride (0.03%), and washed
again. Slides were then dried at RT and hybridized over-
night at 55#C with 1.5 lg/mL digoxigenin (DIG)-labeled
probe in hybridization solution: 50% formamide, salts
10" pH 7.2 (NaCl 3M, Tris HCl 0.1M, NaH2PO4 0.1M, 2%
Ficoll 400 (Sigma), 2% polyvinyl pyrrolidone (Sigma)), DTT
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2M (Sigma) in 10 mM sodium acetate pH 5.2, polyadenilic
acid (Sigma) 10 mg/mL, ribonucleic acid (Sigma) 9.2
mg/mL, transfer type x–SA (Sigma) 7 mg/mL, 10% dex-
tran sulfate (Sigma).
After hybridization, slides were washed in 5" SSC-
bmercaptoethanol at RT for 30 minutes. Then they were
washed in 50% formamide-1" SSC-bmercaptoethanol at
65#C for 30 minutes, several times in the NTE solution
(5M NaCl, 1M Tris-HCl pH 8.0, 0.5 M EDTA pH 8.0) at RT,
then in 2" SSC and 0.2" SSC. Slides were put in a
humidified chamber with buffer B1 (1M Tris-HCl pH 7.5, 5
M NaCl), blocked in HI-FBS (heat-inactivated fetal bovine
serum)-B1 (10%90) for 60 minutes. Each slide was
treated with 1:1,000 anti-DIG (Roche) in HI-FBS-B1, cov-
ered with a parafilm coverslip, and incubated overnight
at 4#C.
Chromogenic-stained slides were washed several
times with buffer B1 and with buffer B2 (0.1 M Tris-HCl
pH 7.5, 0.1 M NaCl, 50 mM MgCl2 pH 9.5) and stained
with NBT 3.5 lL (Roche)-BCIP 3.5 lL (Roche) in 4 mL B2.
After 10 minutes the reaction was observed under the
microscope and stopped when the transcript signal level
was detectable. Slides were then washed several times in
buffer B1, then in PBS 1". Slides were mounted with one
20 lL drop of PBS 1" 30% glycerol solution and a glass
coverslip, sealed with enamel, and stored at 4#C.
In situ probes cloning and synthesis
Primer sequences were designed in order to clone the
complete 765-basepairs-long coding sequence (CDS) of
mouse (Mus musculus) Prnp gene in pGEM–T vector
(Promega, Madison, WI): 50-TCATCCCACGATCAGGAA
GATGA-30; 50-ATGGCGAACCTTGGCTACTG-30. Sense and
antisense probes were transcribed in vitro with SP6 and
T7 RNA Polymerase (Promega) in the presence of DIG-
UTP RNA Labeling Mix (Roche), then stored at !80#C.
The efficiency of labeling was checked and confirmed by
Northern blot assay, which revealed a single band at the
expected basepairs number.
RESULTS
Prnp gene expression detected throughout
the developmental mouse brain
To investigate Prnp gene expression, PrP mRNA expres-
sion was analyzed in several regions of the mouse brain
during pre- and postnatal development. In situ hybridiza-
tions were performed on 20-lm-thick coronal cryosec-
tions of mouse brains. Prnp gene expression in the brain
was analyzed in 14.5- and 16.5-day-old embryos (E14.5,
E16.5), in 1- (P1) and 7- (P7) day-old mice, and in adult
mice. As negative control, sections from Prnp null mice
were hybridized with the PrP riboprobes (data not
shown).
Between E14.5 and E16.5 noticeable labeling was
detected in brain regions known to have a highly active
cellular proliferation, such as the ventricular zone (VZ) of
the neocortex of the lateral ventricles (Fig. 1A,B) and the
neuroepithelia of the third ventricle (IIIv) (Fig. 1I–L). In
addition, Prnp signal was detected underneath the mar-
ginal zone (MZ) in the superficial cortical plate (CP),
where newborn neurons were. At P1 the signal spanned
the entire CP (Fig. 1C,D), whereas at P7 it was mainly re-
stricted to the superficial CP, where the youngest neu-
rons were (Fig. 1E,F). At P7 it was possible to observe a
decrease of the signal in the subventricular/ependymal
zone (SVZ/E) and in the subplate zone (SP), while it
increased in the outer layers of the cortex (layers 6-2)
(Fig. 1E,F).
At P7 it was possible to observe strong Prnp gene
expression in other brain areas, such as the CA1 and the
DG fields of the hippocampus (Fig. 2).
Moreover, during postnatal development and in the
adult the expression pattern of PrP mRNA was constantly
detectable in the olfactory bulbs. Hybridization signals
were found in the mitral cells layer (Mi), along the wall of
the olfactory bulb ventricle, and in the glomerular layer
(GL) at P7 (Fig. 3A,B); this expression pattern remained
constant during adult life (data not shown). These results
are in agreement with previous descriptions (Le Pichon
and Firestein, 2008). As expected, a signal was also
detected in the frontal cortex.
By E16.5, intense expression was also found in non-
neuronal tissue, such as the choroid plexus (ChP) of the
ventricles, both at the mRNA and protein level (Fig. 3C–
F). Specifically, PrPC immunoreactivity was detected in
the apical surface of the epithelial cells, on the side facing
the ventricle (Fig. 3F).
Dynamics of PrPC expression in the
developmental mouse brain
The overall distribution of PrPC in the developmental
mouse brain was also examined by immunohistochemis-
try technique. The dynamics of PrPC expression during
prenatal and postnatal development were examined in
coronal and longitudinal brain sections of E14.5, E18.5,
P1, P4, P7, P9, and adult mice. The hippocampus was the
region with the earliest and highest PrPC immunoreactiv-
ity. Starting from E18.5 to adult life the hippocampus was
labeled by Fab D18 in all parenchyma, with a net increase
in PrPC immunoreactivity in the stratum lacunosum
moleculare (str l m) (Fig. 4A,B). This layer of the hippo-
campus contains a high number of synapses from hippo-
campal internal interneurons and from external inputs,
PrPC developmental expression and regulation
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such as the enthorinal cortex (Deng et al., 2006). Strong
PrPC immunoreactivity was also observed in the fimbria
(Fi) of the hippocampus (Fig. 4C–L). In this structure,
PrPC-immunoreactivity was first observed at E18.5 and
progressively increased during development (Fig. 4E–H).
Next to the fimbria of the hippocampus, the stria
Figure 1. Prnp shows a patterned developmental expression in mouse brain. A,B: In situ hybridization of E14.5 brain coronal section. A:
No positive cell was detected in the neocortex area using negative sense probe. B: Positive antisense probe shows that Prnp was detected
in the ventricular zone (VZ). In addition, Prnp signal seems to be underneath the marginal zone (MZ) and in the superficial cortical plate
(CP). Less intense signal was detected in the subventricular zone (SVZ) and in the subplate zone (SP). C,D: In situ hybridization of P1 brain
coronal section. The antisense probe (D) shows signal for Prnp spanning the entire CP (layer 6-2). Negative control sense probe shows
specificity of the signal in (C). E,F: Expression pattern of Prnp gene in the cortex layers of P7 postnatal stage. The positive signal of Prnp
(F) is mainly concentrated to the superficial CP, whereas it progressively decreases in the subventricular/ependymal zone (SVZ/E) and in
the subplate zone (SP). No signal was detected with the negative probe (E). G,H: Immunohistochemical staining of E14.5 mouse brain
shows no expression of the mature PrPC in the neocortex. PrPC (in H) and nuclei (blue, in G) were stained, and no PrPC immunoreactivity
was detected. I,J: The expression of Prnp was detected in the neuroepithelia of the third ventricle (IIIv) at E14.5 using antisense probe (J),
whereas no signal was detected using negative sense probe (I). Scale bars ¼ 100 lm in G,H; 25 lm in I,J.
Figure 2. Expression of Prnp in the postnatal hippocampus. A–D: In situ hybridization of P7 hippocampal coronal section. A,B: Prnp signal
was detected in the CA1 and in the DG cells in the hippocampus (B); no signal was detected with the control probe (A). C,D: Higher mag-
nification of the CA1 pyramidal cells, indicating a clear perinuclear staining of Prnp expression (D). No signal was detected when using the
negative sense probe (C). Scale bars ¼ 50 lm.
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terminalis (St) also showed a high level of PrPC immunore-
activity (Fig. 4C–L), and paralleled the developmental
expression of PrPC of the fimbria (Fig. 4E–H). The stria ter-
minalis is the main nervous output of the amygdala up to
thalamic nuclei (Lee and Davis, 1997). The immunostaining
clearly highlighted that PrPC expression in these white mat-
ter fiber bundles is very high and well defined (Fig. 4I–L).
The thalamus was another region showing basal PrPC
expression during neurodevelopment (Fig. 5). Within the
thalamus the fornix, the anatomical continuation of the
hippocampal fimbria, showed an intense and definite
PrPC-immunoreactivity (Fig. 5A). The specificity of PrPC
expression for particular brain white matter tracts could
be appreciated by the complete lack of PrPC staining of
the mammillothalamic tract (Fig. 5A–C). Moreover, the
fasciculus retroflexus (Fr) specifically showed a high
staining for the mature protein during development (Fig.
5D–H). As for the fimbria of the hippocampus and the
stria terminalis, PrPC immunoreactivity was first observed
at E18.5 and progressively increased during development
both for the fornix (Fig. 5I–M) and for the fasciculus retro-
flexus (Fig. 5N–P).
However, we did not observe any dramatic alterations
in the size or in the morphology of any of these structures
in Prnp!/! animals.
DISCUSSION
In the present study we describe a restricted PrPC
expression in specific brain areas during prenatal and
postnatal brain development. By in situ hybridization we
could identify Prnp gene expression at E14.5 in the VZ,
which is known to be a proliferative brain area, in the su-
perficial CP, underneath the MZ where newborn neurons
are, and in the neuroepithelia of the third ventricle (Fig.
1). The developing choroid plexus epithelium of the ven-
tricular zone is known to contain multipotent neural stem
cells (Tramontin et al., 2003). The MZ is the outermost
layer of the cerebral cortex. Cells of the MZ are known to
play key roles during development such as orchestrating
the development of the cortical layers and contributing to
the GABAergic interneurons in the cerebral cortex (Meyer
et al., 1998). MZ cells have also been shown to guide
cortical afferents to their targets (Marin-Padilla, 1978;
McConnell et al., 1989) and develop a transient neuronal
circuit of crucial importance for setting up the mature cir-
cuitry among CP neurons (Friauf and Shatz, 1991; Ghosh
and Shatz, 1992; Schwartz et al., 1998).
In the neocortex of P1 mouse, Prnp gene expression
was detected in the SVZ/E, located adjacent to the VZ
along the lateral ventricle wall. Importantly, neurogenesis
persists in this part of the brain throughout the animal’s
adult life.
The expression pattern of Prnp in the VZ and SVZ/E
suggests that the Prnp gene could be involved in the cel-
lular proliferation control along development. Indeed, one
report suggests that PrPC positively regulates neuronal
precursor proliferation in the SVZ/E during development
and adult neurogenesis (Steele et al., 2006).
At P1 Prnp gene is expressed throughout the cortical
layers 6-2. At P7 the signal could still be detected in the
cortical layers 6-2, with the strongest signal in layer 2 and
progressively decreasing down to layer 6 (Fig. 1). Prema-
ture neural cells proliferate in the ventricular side and
migrate toward the cortical layers in the developing cere-
bral cortex. Neuronal precursors generated in the ventric-
ular/ependymal zone migrate outwards along the glial
processes to form the CP at the outer surface of the
brain. Since the Prnp expression pattern during neurode-
velopment seems to parallel such a time course of neuro-
nal differentiation, it is possible to argue that Prnp expres-
sion could be implicated in neuronal proliferation and
maturation: Prnp signal detected in neurons of layers 2 to
6 at P7 could be due to the same neurons that were previ-
ously described to express PrP mRNA in the VZ and in the
SVZ/E zones at E14.5 and at P1. However, since PrPC
immunoreactivity in the cortical layers was not observed
during prenatal development, it is possible to hypothesize
that in the cortex PrP mRNA is not translated in PrPC, or,
if translated, the protein is quickly degraded during this
developmental stage.
During brain early postnatal development we found
PrPC strongly expressed in the hippocampus. Differently
from the cortex, in the hippocampus we revealed the
expression of PrPC concomitantly with the presence of
Prnp mRNA (Figs. 2, 4). Indeed, among all brain areas the
hippocampus exhibited the earliest and the highest PrPC
expression. Our results show that, within hippocampus,
the stratum lacunosum-moleculare (str l m) revealed the
highest PrPC expression. As this is a synapse-rich region
Figure 3. Prnp is expressed in the olfactory bulb and in the choroid plexus during development and in adult life. A: At P7 the expression
of Prnp is widespread in the olfactory bulb, with an increased expression in mitral cells layer (Mi) and in the glomerular layer (GL). B:
Higher magnification of the different layers. C–F: PrP is expressed also by the choroid plexus. C–E: Epithelial cells of the choroid plexus
show an intense Prnp signal starting at E16.5 (D) until adult life (E). No signal is detected using the control probe (C). F: At P7 PrPC is
detected in the epithelial cells of the choroid plexus, specifically at the apical surface of the cells toward the ventricle.
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where hippocampal interneurons (Bertrand and Lacaille,
2001) and afferent neuronal inputs (Deng et al., 2006)
make connections (Fig. 6), we can infer that the relatively
high expression of PrPC in this region could possibly be
necessary to the correct development of synapses and, in
turn, to a correct synaptic activity. Several studies sug-
gest that the synaptic compartment could be the critical
site of functional PrPC expression (Herms et al., 1999;
Carleton et al., 2001), and that loss of PrPC function, such
as in Prnp!/! mice, may interfere with the correct, physi-
ological connections between neurons. Indeed, many of
the abnormalities identified in Prnp!/! mice are related
to a hippocampal synaptic dysfunction (Collinge et al.,
1994; Carleton et al., 2001; Curtis et al., 2003; Maglio
et al., 2004; but also see Lledo et al., 1996). Interestingly,
some reports point to central synapses as primary dys-
functional victims also in prion diseases, before neuro-
degeneration occurs (Jeffrey et al., 2000; Cunningham
et al., 2003).
Another phenotype of Prnp!/! mice is their increased
susceptibility to epileptic seizures (Walz et al., 1999). The
core of many forms of seizures are large and synchron-
ized bursts of activity originated, among all the brain
structures, peculiarly in the hippocampus and the neocor-
tex (McCormick and Contreras, 2001). Indeed, increasing
evidence suggests that an altered neurodevelopment,
leading to either brain malformations or injuries, may be
involved in the generation of epilepsy (Hermann et al.,
2008). Our finding of a strong developmental regulation
and expression of PrPC in the hippocampus and in the
neocortex is intriguing, as it may account for the
increased susceptibility of Prnp!/! mice to epileptic seiz-
ures. The lack of PrPC, in fact, may alter the physiological
development of these brain structures, and in turn pro-
voke changes in interneuronal connections and neural
network properties.
Strong PrPC immunoreactivity was also observed in
brain structure involved in the regulation of the thalamo-
limbic system, such as the fimbria/fornix, the fasciculus
retroflexus, and the stria terminalis (Fig. 4, 5). The thala-
molimbic system is involved in the regulation of circadian,
autonomic, and hormonal functions, as well as stress
response behaviors (Herman et al., 2003, 2005; Saper,
2006; Ulrich-Lai and Herman, 2009). The fimbria/fornix
provides the major afferent and efferent projections of
the hippocampus to basal forebrain (Olton et al., 1978);
the fasciculus retroflexus connects the habenular nucleus
to the interpeduncular nucleus and it is known to be inte-
grated in the processing of various subsystems involved
in the sleep–wake mechanisms (Valjakka et al., 1998);
the stria terminalis is a limbic forebrain structure that
receives heavy projections from, among other areas, the
basolateral amygdala, and projects in turn to hypothala-
mic and brainstem target areas that mediate many of the
autonomic and behavioral responses to aversive or
threatening stimuli (Walker et al., 2003) (Fig. 6). Thus, the
high developmental expression of PrPC in brain fiber bun-
dles participating in the regulation of the thalamolimbic
circuitry may reveal a potential role for PrPC in the correct
development, structuring, and functioning of this complex
neural system. Interestingly, the lack of PrPC in Prnp!/!
mice was proved to be responsible for alterations that
can be related to incorrect performance of this neural
system. These alterations include altered circadian activ-
ity rhythms and sleep activities (Tobler et al., 1996), defi-
cits in hippocampal-dependent spatial learning (Criado
et al., 2005), altered stress response and neuroendocrine
stress functions (Sanchez-Alavez et al., 2007), altered
fear-induced behavior (Lobao-Soares et al., 2008), and
disregulation of the hypothalamic-pituitary-adrenal axis,
the ‘‘stress’’ axis (Sanchez-Alavez et al., 2008). Intrigu-
ingly, pathological alterations that can be related to a dys-
function of the thalamolimbic system have been
described also in some cases of prion diseases, such as
corticosteroid disturbance (Gayrard et al., 2000; Voigt-
lander et al., 2006). Moreover, patients suffering the
genetic prion disease FFI show predominant sleep, neuro-
endocrine, and autonomic dysfunction (Montagna et al.,
2003). Hence, the absence of PrPC in Prnp!/! mice, or
its possibly altered physiological functioning in certain
cases of prion diseases, gives rise to pathological altera-
tions associated with incorrect neural information proc-
essing by brain structures contributing to the regulation
of the thalamolimbic neurocircuitry.
In summary, we have identified PrPC expression to be
highly regulated during neurodevelopment, and in
Figure 4. PrPC expression in the hippocampus during development. A,B: At P7 PrPC (in red; A) is detected throughout the hippocampus,
and in particular at high levels in the stratum lacunosum-molecolare (str l m), a synapse-dense region. No signal for PrPC is yet detected
in the cortex. A merged image is shown in B (PrPC, in red; neurofilament, in green; nuclei signals in blue). C–H: PrPC is specifically and
highly expressed by the fimbria of the hippocampus and the stria terminalis at P7 (C,D). The fimbria of the hippocampus (Fi) and the stria
terminalis (St) express high level of PrPC also at embryonic stages (E18.5), and progressively increase the level of expression during post-
natal development: P1 (F), P4 (G), and P7 (H). I,J: Higher magnification of longitudinal (I) and coronal (J) section of the fimbria of the hippo-
campus and the stria terminalis, highlighting the net boundaries of PrPC-expression between other brain regions and these structures.
Scale bars ¼ 50 lm.
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Figure 5. Thalamic expression of PrPC during development. Immunohistochemical staining for PrPC (in red; A,C,D–G,I–N) and neurofilament
(in green; B,C). A merged image is shown in (C). A–C: At P7 PrPC is detected in the thalamus, with abundant and specific expression in
fornix (A). The specificity of PrPC expression by this structure is highlighted by the counterstaining of neurofilaments, which labels both
the mammillothalamic tract and the fornix (B). Only the fornix shows colocalization of PrPC and neurofilament signals (in yellow; C). D–H:
P7: PrPC expression is detected also specifically in the fasciculus retroflexus (or habenulointerpeduncular tract). The fasciculus retroflexus
express PrPC all along its length, with clear boundaries, highlighted by coronal (D–F) or longitudinal (G) PrPC staining. Counterstaining of
nuclei (in blue; H) underlines the low number of nuclei in this white matter structure. I–N: Developmental PrPC expression by the fornix
and the fasciculus retroflexus (Fr). Both these structures show a progressively increasing level of expression of the protein during develop-
ment, starting from E18.5 (fornix and Fr, respectively; I,L), to P1 (respectively, J,M), until P7 (respectively, K,N). Scale bars ¼ 50 lm.
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particular we have described a high level of expression of
PrPC in specific nerve fiber bundles involved in the tha-
lamolimbic system regulation. The high developmental
expression of PrPC in these white matter tracts might
reflect an active axonal transport of the prion protein
through these fiber bundles; indeed, PrPC can be trans-
ported along axons (Borchelt et al., 1994; Moya et al.,
2004), and in particular, in the case of the fimbria/fornix,
PrPC expression in these tracts could be due to axonal
transport from the hippocampus.
This strong developmental regulation and the main syn-
aptic localization of PrPC in adult neurons (Herms et al.,
1999; Moya et al., 2000) could implicate PrPC in the cor-
rect structuring and functioning of specific brain circuits.
The lack of PrPC, such as in Prnp!/! animals, could be
more detrimental for brain regions requiring high levels of
expression of the protein during development than in
regions with a lower physiological expression. In turn,
these regions would not be able to form and/or operate
properly, and when challenged by the proper external
stimulus they would respond with a nonphysiological
nervous output, if compared to wildtype situations. In this
perspective, this may also be true for the aberrant func-
tion of PrPC once converted into PrPSc.
Despite PrPC synaptic localization (Moya et al., 2000),
in adult mice it can also be localized in other parts of the
neurons plasma membrane, including dendritic, somatic,
and axonal membranes (Mironov et al., 2003). These find-
ings point to a broader physiological role for PrPC in adult
life than simply a synaptic one. Indeed, besides synapse
formation and function, PrPC was shown to influence
several cellular processes in the nervous system, e.g.,
neuronal survival, intercellular contacts, and signaling,
and maintenance of myelin fibers (reviewed in Aguzzi
et al., 2008). Our data can indeed support the hypothesis
for distinct temporal functions for PrPC as being suppos-
edly involved in circuit formation and refinement during
neuronal development, and in other functions in adult life
once the correct neuronal circuits have been formed.
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Abstract
The cellular form of the prion protein (PrPC) is a sialoglycoprotein widely expressed in the central nervous system (CNS) of
mammalian species during neurodevelopment and in adulthood. The location of the protein in the CNS may play a role in
the susceptibility of a species to fatal prion diseases, which are also known as the transmissible spongiform
encephalopathies (TSEs). To date, little is known about PrPC distribution in marsupial mammals, for which no naturally
occurring prion diseases have been reported. To extend our understanding of varying PrPC expression profiles in different
mammals we carried out a detailed expression analysis of PrPC distribution along the neurodevelopment of the metatherian
South American short-tailed opossum (Monodelphis domestica). We detected lower levels of PrPC in white matter fiber
bundles of opossum CNS compared to mouse CNS. This result is consistent with a possible role for PrPC in the distinct
neurodevelopment and neurocircuitry found in marsupials compared to other mammalian species.
Citation: Poggiolini I, Legname G (2012) Mapping the Prion Protein Distribution in Marsupials: Insights from Comparing Opossum with Mouse CNS. PLoS
ONE 7(11): e50370. doi:10.1371/journal.pone.0050370
Editor: Anthony E. Kincaid, Creighton University, United States of America
Received June 19, 2012; Accepted October 18, 2012; Published November 29, 2012
Copyright: ! 2012 Poggiolini, Legname. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: legname@sissa.it
Introduction
The cellular form of the prion protein (PrPC) is a cell-surface
glycosylphosphatidylinositol-anchored glycopolypeptide abun-
dantly expressed in the central nervous system (CNS), with
expression levels varying among different cell types and brain
regions [1]. The distribution pattern of PrPC has already been
investigated in deep detail in the CNS of several placental
mammalian organisms, including mouse (Mo) [2–6], hamster [7],
cattle [8], sheep [9] and primates [10,11]. Additional studies,
along the same lines of research, have reported the pattern of PrPC
distribution also in avian [12] and fish [13]. The earliest expression
of the protein in mammals has been observed in the hippocampus,
thalamus and hypothalamus and the highest levels of PrPC
expression have been noted in specific white matter fiber tracts [6].
Structurally, mature PrPC expressed by a wide variety of
mammalian species shares a similar fold: while the N-terminus is
largely unstructured, the C-terminus possesses well-defined
secondary and tertiary structures [14,15]. The N-terminus features
an evolutionarily conserved motif denoted as the octapeptide-
repeat region (residues from 51 to 90 in Mo numbering, Figure 1).
The octapeptide-repeat region is able to coordinate the binding of
copper ions, thus implicating a possible role of PrPC in copper
homeostasis [16].
The sequence identity of PrPC among mammals suggests an
important physiological role [17]. However, the function of the
protein has not been fully clarified, mostly due to the fact that
PrPC-null mice (Prnp0/0) do not show remarkable phenotypic
abnormalities [18,19]. Putative PrPC functions are based on its
localization. In particular, the highest expression of the protein in
the hippocampus and, within this brain region, in the stratum
lacunosum-moleculare, suggests a role for PrPC in synaptic structure,
function and maintenance [6]. Additionally, the large number of
PrPC-interacting molecules identified thus far [20] implies that
PrPC may be a dynamic cell surface platform for the assembly of
signaling modules.
Defining the function of PrPC is also a prerequisite for
understanding TSEs, or prion diseases, as they are attributed to
the posttranslational conversion of PrPC into a misfolded,
pathogenic form denoted prion or PrPSc [21]. This group of rare
neurodegenerative maladies, affecting humans and animals alike,
can be sporadic, genetic or iatrogenic. They include Creutzfeldt-
Jakob disease (CJD), fatal familial insomnia and Gerstmann-
Stra¨ussler-Scheinker syndrome in humans, scrapie in sheep and
goats, bovine spongiform encephalopathy in cattle, and chronic
wasting disease in cervids.
A still controversial aspect in TSEs is the different ability of
prions to infect some mammalian species and not others. So far no
naturally occurring TSEs have been reported in rabbit, horse or
any marsupial species. A possible explanation for this argues that
the PrPC primary sequence, together with local structural
variations within the C-terminus globular domain, might account
for prion resistance in different mammals [22]. However, little is
known about the regional distribution of PrPC in the CNS of
mammalian species that seem resistant to TSEs. Differences in
PrPC expression in mammalian species, for which no naturally
occurring TSEs occur, may shed light on different susceptibility to
these maladies.
To gain insights into this neglected issue we analyzed PrPC
distribution along the neurodevelopment of the metatherian
mammal South American short-tailed opossum (Monodelphis
domestica) (hereafter Op). This animal model is used in develop-
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mental studies mainly because of the rudimental stage of
development of the newborn pups, which resemble 11- or 12-
day Mo embryos [23,24]. In the newborn Op pup the CNS is still
at an embryonic stage [23], because its development is completed
during postnatal life.
The Op genome sequencing has provided an important tool for
comparison with Eutherians, such as human and Mo, and has
contributed to our knowledge about the evolution of Amniota
[25,26]. Because of its evolutionary position between avian and
eutherian genomes, Op represents an invaluable model for
evolutionary comparison. Ultimately, its small size, ease of care
and the non-seasonal breeding make Op a suitable laboratory
animal model [27,28].
The assignment and characterization of Op prion protein (PrP)
gene has revealed that OpPrP and MoPrP share approximately
70% sequence identity [29]. Sequence variations are most
prominently localized on the N-terminus copper binding sites
region: while MoPrP contains one nonapeptide, and four
octarepeats of identical sequence, OpPrP features five different
decarepeats, which are able to bind copper ions [30,31].
Additionally, the region from residue 91 to 110 (in MoPrP
numbering), which also binds copper, is less conserved in OpPrP
(Figure 1).
In this work, the expression profile of OpPrP was characterized
at different postnatal developmental stages of Op CNS using
Western blotting and histoblot techniques. To compare OpPrP
and MoPrP distribution in CNS, we examined the expression of
PrPC in postnatal 30-day-old (P30) mice – which resemble young
adult Op in the overall development – under the same
experimental conditions.
The most striking difference between the two mammals
concerned the lower PrPC detection in the Op white matter
structures. The different organization pattern observed might offer
insights into the role of PrPC in neurodevelopment and in
neurocircuitry formation in Op and other mammals [32].
Ultimately, it might also expand our current knowledge of PrPC
function in mammals.
Materials and Methods
Animals
All experiments were carried out in accordance with European
regulations [European Community Council Directive, November
24, 1986 (86/609/EEC)] and were approved by the local
veterinary service authority. FVB wild-type, and FVB Prnp0/0
mice [33] were used in these experiments. Animals were obtained
from the colony maintained at the animal house facility of the
University of Trieste, Italy. Animals were staged by systematic
daily inspection of the colony for newborn litters. P0 corresponds
to the day of birth [34]. Each experiment was performed at least in
triplicate. Mice and Op pups were decapitated. Mice (at P30) and
Op adults (at P45, P50, and P75) were killed by cervical
dislocation. For histoblotting, brains were rapidly harvested,
immediately covered in powdered dry ice and included in the
embedding medium OCT (Optimal Cutting Temperature).
Histology
CNS specimens were fixed in 4% paraformaldehyde-PBS
overnight at 4uC, cryoprotected in 30% sucrose/PBS and cut
coronally at 20 mm. Cryosections were mounted on Fischer
SuperFrost Plus slides and subsequently processed for histology.
Figure 1. Comparison of amino acid sequences and secondary full-length prion protein structure of selected mammalian species:
mouse (MoPrP; Mus musculus, GenBank accession number: AAA39997), human (HuPrP; Homo sapiens, AAA60182), Syrian hamster
(ShPrP; Mesocricetus auratus, AAA37091), sheep (OvPrP; Ovis aries, ABC61639), elk (ElPrP; Cervus elaphus nelsoni, AAB94788), bank
vole (BvPrP; Clethrionomys glareolus, AAL57231), horse (EcPrP; Equus caballus, ABL86003), rabbit (RaPrP; Oryctolagus cuniculus,
AAD01554), tammar wallaby (TwPrP; Macropus eugenii, AAT68002) and opossum (OpPrP; Monodelphis domestica, CBY05848).
doi:10.1371/journal.pone.0050370.g001
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Histoblots
The histoblot technique was performed according to the
protocol described by Taraboulos et al. [35] with a few
modifications. Briefly, uncoated microscope slides (Menzel-Glaser,
Madison, WI) carrying 20 mm-thick brain serial coronal sections
were pressed onto a nitrocellulose membrane wetted in lysis buffer
(0.5% sodium deoxycholate, 0.5% Nonidet P-40, 100 mM NaCl,
10 mM EDTA, 10 mM Tris-HCl, pH 8.0), incubated for one
hour at room temperature in 0.1 M NaOH and rinsed 3 times for
1 minute in TBST 1X (50 mM Tris-HCl, 150 mM NaCl, 0.1%
Tween20, pH 7.4). Blots were blocked for 90 minutes in 5% non-
fat dry milk-TBST 1X. They were incubated overnight at 4uC
with the primary antibody anti-PrPC humanized Fab D18 [36]
purchased from InPro Biotechnology (South San Francisco, CA;
ABR-0D18) and used at a final concentration of 1 mg/mL. This
antibody shows high affinity for the region encompassing residues
133 to 152 (in Mo numbering), which is highly conserved in
different mammals (Figure 1). Membranes were extensively
washed in TBST 1X and incubated for one hour with secondary
antibody diluted in blocking mix. The signal was achieved using
SIGMAFASTTM 3,39-Diaminobenzidine tablets (Sigma) accord-
ing to the protocols of the supplier. All data are representative of at
least three independent experiments.
Nissl staining
Twenty-micrometer fixed frozen cryostat sections, mounted on
slides, were air-dried for 60 minutes, stained in 0.1% cressyl violet
(Sigma) at 40uC for 7 minutes and then rinsed in distilled water.
Slides were soaked in 95% ethyl alcohol for 5 minutes and
dehydrated in 100% alcohol for 5 minutes. Before mounting on
glass slides (Sigma) with resin medium (Eukitt, Bio-Optica) slides
were cleared twice in xylene for 5 minutes.
Western blotting analysis
Total brains or different brain regions were dissected using a
stereomicroscope (Nikon SMZ 800) and immediately frozen in
liquid nitrogen. Tissues were homogenized in RIPA buffer
(150 mM NaCl, NP-40 1%, sodium deoxycholate 0.5%, SDS
0.1%, 50 mM Tris, pH 8.0) with Glass/Teflon Potter Elvehjem
homogenizers and spun at 1000 g at 4uC for 5 minutes. The total
protein amount was determined using the BCA Protein Assay Kit
(Thermo Scientific Pierce). Fifty mg of total protein was then
electrophoresed through 10%–SDS polyacrylamide gels and
transferred to nitrocellulose membranes. Membranes were probed
with monoclonal antibody Fab D18 and developed by enhanced
chemiluminescence (Amersham ECL Western Blotting Systems,
GE Healthcare). Band intensity was quantified using the UVI Soft
software (UVITEC, Cambridge).
Results
PrPC expression in the Op brain is developmentally
regulated
PrPC protein extracts from adult knockout PrP (MoPrP2/2),
wild-type PrP (MoPrP+/+) mice and adult Op were compared
using Western blotting (Figure 2A). The expected di- (,37 kDa),
mono- (,30 kDa) and un- (,27 kDa) glycosylated forms were
detected by Fab D18 monoclonal antibody both in MoPrP+/+ and
Op lanes. The absence of signal in the lane loaded with MoPrP2/2
sample showed the specificity of the antibody. Although all the lanes
were loaded with the same amount of total protein, the lower
intensity of Op PrP signal compared to MoPrP+/+ signal might be
due to a lower affinity of the antibody for the Op PrP than for
MoPrP+/+. Alternatively, these results might indicate a lower PrPC
expression in adult Op than in Mo. Figure 2B shows the PrPC
pattern observed by immunoblotting from P1 to P45. A predom-
inance of the diglycosylated form of the protein at ,37 kDa and of
the monoglycosylated form of the protein at ,30 kDa was
observed. A minor band corresponding to the non-glycosylated
form of the protein was detected at ,27 kDa. This expression
pattern resembles those observed in eutherian Syrian hamster (SHa)
and Mo brains [37].
The PrPC expression from P10 to P70 was also evaluated in the
thalamus, olfactory bulbs, cortex and hippocampus (Figure 2C). In
all these regions an increase in PrPC expression was observed until
P50. In adulthood the expression of PrPC decreased slightly or
remained at plateau. Like in SHa [7], a tendency to an increase in
PrPC signal was observed in the olfactory bulbs at P75.
Regional expression of PrPC
Since PrPC was not detected by immunofluorescence staining
performed following well-established protocols described in the
literature, we investigated the regional distribution of PrPC in the
Op brain at P15, P20, P37 and P70 by histoblot (see Materials
and Methods) [35]. After the completion of cortico-cerebral
neurogenesis [34], at P15 and at P20 strong PrPC immunore-
activity was detected in the hippocampus, in the thalamus and in
the neocortex. In the hippocampus, a signal was observed in the
parenchyma, but not in the pyramidal layer of the Ammon’s
Horn (CA1-CA3) nor in the granule cell layer of the dentate
gyrus (DG) (Figure 3A–B). At P37 (Figure 4A and B) a dense
PrPC signal was identified in gray matter structures such as
thalamus, cortex and hippocampus. In the latter, PrPC immu-
nostaining was deep in the stratum radiatum and in the stratum
oriens. As observed at P20, the signal was virtually absent in the
pyramidal cells of the CA and in the granule cells of the DG. In
the hilar region, immunoreactivity (IR) was minimal. IR was
observed around the dorsal and the lateral parts of the thalamus
(Figure 4A), encompassing structures involved in the communi-
cation between cortex and thalamus [38].
The PrPC signal was also evaluated at P70, after the time of
weaning [23]. A low IR was observed in white matter areas such
as the internal and external capsules (Figure 5B). As observed at
P37, in the P70 hippocampus the strongest IR was present in the
oriens and radiatum strata. A less intense signal was detected in the
stratum lacunosum-moleculare (Figure 5C). The expression pattern
profile observed in adult Op hippocampus is similar to that in
SHa [7].
PrPC immunolocalization in Mo brain coronal sections
Histoblots of P30 MoPrP+/+ brain coronal sections were
immunostained to measure differences in PrPC localization
between Op and Mo (Figure 6A and B). The lack of IR in
P30 MoPrP2/2 coronal sections (Figure 6C and D) confirmed
the specificity of the D18 signal. Ponceau staining was performed
to ensure the presence of the section on the nitrocellulose
membrane.
The pattern of PrPC distribution in P30 MoPrP+/+ was detected
in many structures throughout the brain (Figure 6A and B). At P30
strong IR was found in the alveus, a thalamo-limbic structure of
fornix fibers surrounding the stratum oriens that contains the axons
of pyramidal neurons. As previously reported [6], a well-defined
PrPC signal was present in the stratum lacunosum-moleculare
(Figure 6A). Strong labeling of the white matter fiber bundles
was particularly evident at the level of the corpus callosum – the
major interhemispheric fiber bundle in eutherians – and in the
anterior commissure, also involved in interhemispheric commu-
nication [39]. Within the limbic system, a signal was detected in
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the hippocampal fimbria, in its continuation, the fornix and in the
hippocampus. In the neocortex (NCx), staining was detected in a
region adjacent to the ependymal layer.
Discussion
Over the last twenty years, the expression of PrPC in the CNS of
placental mammals, such as Mo and SHa, has been intensively
investigated. Here we described a restricted PrPC expression
during Op brain development. Our data appear to corroborate
current evidence of a developmentally regulated expression of
PrPC in all mammals. The direct comparison between Op and
MoPrPC expression in CNS showed striking differences in distinct
brain regions, such as white matter structures and hippocampus,
thus suggesting possible functional implications for the role of PrPC
in marsupials.
Technical remarks about PrPC detection in Op brain
The routine histological techniques might not be sensitive
enough to map PrPC expression in the Op brain. We tested
different immunofluorescence protocols in combination with
several monoclonal antibodies, but none of them appeared to
work (data not shown). We speculated that these technical
difficulties experienced with the traditional immunohistochemical
staining techniques might be due to a weak antibody affinity for
OpPrP, possibly ascribable to epitope masking as a result of a
different membrane environment. Alternatively, PrPC signal might
be masked by another molecule, which could make the binding of
the antibody to the antigene inaccessible.
To overcome these difficulties we decided to use the
immunohistoblot technique described by Taraboulos et al. [35]
to map the regional distribution of PrPSc in the brain of diseased
Figure 2. Confirmation of antibody specificity and developmental expression of PrPC in opossum CNS. (A) Western blotting of Op,
MoPrP+/+ and MoPrP2/2 whole brain homogenates confirmed the specificity of the PrPC signal. The blot was then reprobed with b-tubulin antibody
to demonstrate equal loading of samples (50 mg per lane). (B) Western blotting analysis of equal amounts of total brain homogenate (50 mg per lane)
at different developmental stages showed a major electrophoretic band at 37 kDa, which corresponds to the diglycosylated form of the protein. b-
tubulin was used as loading control. (C) Western blotting of indicated brain regions at different developmental stages showed a relevant change in
PrPC expression during postnatal development. Each data point represents the mean absorbance 6SEM of 3 females from different litters. All the
absorbance values were normalized against b-actin.
doi:10.1371/journal.pone.0050370.g002
Figure 3. PrPC expression in histoblots of P15 and P20 opossum brains. (A–B) In coronal sections of P15 and P20 a PrPC signal was detected
in the thalamus (Th), in the neocortex (NCx) and in the hippocampus (H). The pyramidal cell layer (pyr) and the granule cell layer (gr) of the
hippocampus were not stained by PrPC (Bars: A–B 4 mm).
doi:10.1371/journal.pone.0050370.g003
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SHa. The use of 0.1 M sodium hydroxide enhanced the binding of
PrP antibodies [40] thus allowing for the detection of a clear PrPC
signal in the cryostat sections of the freshly frozen Op brain tissues
in this study.
Comparison of PrPC distribution between marsupials and
placental mammals
Our results showed that from the day of birth (P1) up to
adulthood (P75) PrPC was detectable by Western blotting in whole
brain homogenates (Figure 2B) with the strongest PrPC signal in
the uppermost diglycosylated band (,37 kDa) and the weakest
signal in the lowest non-glycosylated PrPC band (,26 kDa). A
change in PrPC relative abundance was observed during Op brain
development, corroborating previous evidence of a developmen-
tally regulated expression of PrPC. In the different brain regions
under consideration, PrPC levels either remained at plateau or
decreased slightly in adulthood (Figure 2C). Interestingly, after the
time of weaning a tendency to an increase in PrP expression was
observed in the olfactory bulbs. As postulated for placental
mammals [7] this finding might be related to ongoing plasticity of
the olfactory bulbs also in marsupials. However, no evidence is
available yet to suggest that there is indeed plasticity in the
olfactory bulbs of adult marsupials.
At P37 we observed a strong PrPC immunoreactivity in the
thalamus, a region which has a strong nonphotic influence on
sleep and circadian rhythmicity [41]. This finding suggested an
evolutionary conserved involvement of PrPC in sleep homeostasis
in the Op, in which a functioning circadian timing system exists
[42–44].
Before weaning, PrPC was detectable in the parenchyma of the
hippocampus (Figure 3B). Interestingly, in different eutherian
species, PrPC preferentially localizes in specific hippocampal
layers. In the adult Op (Figure 5C) and SHa [7] the strongest
immunoreactive strata are the oriens and the radiatum, whereas
MoPrPC specifically localizes in the stratum lacunosum-moleculare
(Figure 6A). These results seem to suggest a different regulatory
role of PrPC in the synaptic activity of different species. The lack of
PrPC in the nerve cell bodies was implied by the absence of signal
Figure 4. PrPC distribution in a P37 opossum brain. (A–B) Coronal sections in the caudal diencephalon from a P37 opossum were stained for
PrPC in the thalamus (Th) and in the parenchyma of the hippocampus. (A) In the ventral thalamus, a strong IR was observed in the reticular nucleus
(Rt) and in the nucleus reuniens (Re). No IR was observed in the optic tract (Ot). In the hypothalamic area (H) the immunoreactivity was lower than in
the thalamus. (B) A strong PrPC signal was observed in the stratum oriens (or) and in the stratum radiatum (rad) of the hippocampus. A low PrPC
immunoreactivity was observed in the hilar region (h), while the pyramidal (pyr) and granule (gr) cell layers of the CA1-CA3 and DG were devoid of
immunostaining (Bars: 1 mm).
doi:10.1371/journal.pone.0050370.g004
Figure 5. Coronal sections of opossum brain at P70 (A–C). In (A) the coronal section was Nissl-stained. In the adult opossum (B) a strong signal
was predominantly present in the hippocampus. Marginal signal was also detected in the caudate nucleus (C), in the internal capsule (iC) and in the
putamen (Pu). A very residual signal was observed in the external capsule (eC). In (C) the specific distribution of PrPC in the different hippocampal
layers was analyzed. Staining in the lacunosum and moleculare (lac/mol) was lower than in the oriens (Or) and the radiatum (Rad). PrPC
immunoreactivity was also observed in the subiculum (Sb) the main output of the hippocampus. (Bars: 0.5 mm).
doi:10.1371/journal.pone.0050370.g005
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in the pyramidal cell layer and granule cell layer of the dentate
gyrus in both Mo and Op.
The most striking difference observed between the two species
was the different localization of PrPC in the white matter. The
lower PrPC signal in Op white matter structures argues for a lower
expression of the protein by glial cells and neuronal axons. In P30
mice instead, a strong PrPC immunoreactive signal was detectable
in the corpus callosum, a specific eutherian structure enriched in
myelinated axons and involved in interhemispheric communica-
tion [45].
Implications for TSE pathology
The different ability of prions to infect certain species is
apparently encoded by their structural features, which result in
different physio-pathological outcomes [46]. Indeed some species
may result resistant to prion infection. This strain-like behavior is
known as the prion transmission barrier. However, under
controlled laboratory conditions, prions are able to adapt and
infect species previously believed to be TSE resistant, as was
recently reported in rabbits infected by the murine ME7 prion
strain using protein misfolding cyclic amplification (PMCA)
techniques [47].
Structural studies on the recombinant PrP of mammals for
which no TSEs have been reported in natural conditions [e.g.
horse, rabbit and the marsupial Tammar wallaby (Macropus
eugenii)], postulated that resistance to prions might be due to some
structural features in the globular domain of those mammalian
PrP sequences [48–50]. The OpPrP sequence presents an
outstandingly large number of amino acid substitutions at the N-
terminus in the copper binding sites and, within the C-terminus
domain, in epitopes (residues 163–174 and 221–230 in Mo
numbering, Figure 1) critical for prion conversion [22,51–54].
Based on this sequence identity analysis, it is possible to argue that
these amino acidic differences might have an impact on the ability
of OpPrP to sustain prion conversion. On the other hand, if
structural differences in mammalian PrP are important for
understanding the molecular mechanisms of TSEs, the neuronal
distribution of PrPC in mammalian species that are putatively
resistant to prion diseases should be considered.
It is noteworthy that PrPSc accumulates in the white matter
areas of Mo and SHa brains, thus suggesting that glial cells may be
the primary targets for prions [35,55]. Indeed, the infectious agent
has been shown to spread from the needle track along white
matter pathways towards the gray matter [56]. This hypothesis is
strengthened by pathological studies in human brains of terminal
CJD patients showing axonal damage, hence suggesting a
transport of prions through white matter pathways [57].
Although prion diseases have not been reported in the Op so
far, the differential expression profile might account for a different
susceptibility to prions in general or to diverse prion strains in
particular, as well as for a different pattern of PrPSc accumulation
and propagation between placentals and marsupials. To under-
stand the biological and neurological significance of our observa-
Figure 6. Localization of PrPC in P30 MoPrP+/+ brain and control of signal specificity. (A) At P30 a well-defined signal was present in the
hippocampal stratum lacunosum-moleculare layer (lac/mol) and in the alveus (alv) lying just deep to the stratum oriens layer (or). (B) In the septum-
caudatum, PrPC signal was detected predominantly in white matter fiber bundles, such as the anterior commissure (ac) and the corpus callosum (cc).
The dark dots observed in the caudate-putamen (CPu) are fiber fascicles cut on end. (C) At P30, the lack of IR in MoPrP2/2 coronal section confirmed
the signal specificity. (D) The presence of the brain section on the nitrocellulose membrane was confirmed by Ponceau staining. (Bars: A–D 0.5 mm).
doi:10.1371/journal.pone.0050370.g006
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tions, it would be of interest to attempt specific prion infectivity
experiments in this mammalian model.
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